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INTRODUCTION  
 With increasing world population, the need for health care is increasing. For decades an 
acute disease or chronic illness is being clinically treated through delivery of drugs to the 
patients in form of some pharmaceutical dosage forms like tablets, capsules, pills, creams, 
liquids, ointments, aerosols, injectables and suppositories. Presently these conventional dosage 
forms are primarily prescribed pharmaceutical products and available over-the-counter. To 
achieve and maintain the concentration of an administered drug within therapeutic effective 
range it is often necessary to take drug dosage several times and this result in a fluctuating drug 
levels in plasma. Controlled drug delivery systems have been introduced to overwhelm the 
drawback of fluctuating drug levels associated with conventional dosage forms. 
THREE BASIC MODELS OF DRUG DELIVERY 
TARGETED DRUG DELIVERY 
 It refers to the systemic administration of a drug-carrier with the goal of delivering the 
drugs to specific cell types, tissues or organs. 
A. MODULATED RELEASE SYSTEMS: 
 It implies the use of a drug delivery device that releases the drug at a variable rate 
controlled by environmental conditions, biofeedback, sensor input or an external control device. 
B. CONTROLLED DRUG DELIVERY 
 It refers to the use of a delivery device with the objective of releasing the drug into the 
patient body at a predetermined rate, or at specific times or with specific release profiles. 
 Apparently, there has been an accelerating realization for the need of controlled drug 
delivery as evinced by the multitude of systems developed and under development. The drug 
therapeutic indices could be maximized while incidences of adverse reactions or side effects 
could be minimized by regulating the drug release in a well defined controlled manner. The latter 
eliminates or excludes haphazard and uncontrolled blood plasma profiles associated with 
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conventional dosage forms. With properly designed or customized systems the concentration of a 
drug substance in blood plasma pool and site of action follows an exquisite temporal pattern 
while extraneous sites receive minimal drug quantity resulting into an improve therapeutic 
performance. A variety of approaches and materials has been proposed, which could effectively 
be used in designing and construction of systems with potential to provide predictable, precise 
and reproducible pattern of controlled release or even site specific drug delivery. 1 
ORAL CONTROLLED DRUG DELIVERY 
Oral route has been the commonly adopted and most convenient route for the drug 
delivery. By considering the conventional dosage form of a drug and the drug profile data, such 
as dose, absorption and elimination rate constants, metabolic properties, drug properties and the 
quantity of drug needed, one can determine the desired release rate of the drug from controlled 
release dosage form. (Figure 1.1) 
Controlled drug delivery is one which delivers the drug at a predetermined rate, locally 
or systemically, for a specified period of time. 2 
 
Fig. 1.1: Plasma drug concentration profile for Immediate, Sustained and 
Controlled release formulations 
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Advantages of controlled drug delivery1 
 Controlled delivery of active agents at predetermined rate. 
 Maintenance of optimal and effective drug level for prolonged duration. 
 Reduction of untoward effects. 
 Increase in patient compliance. 
 Reduction in frequency of dosing. 
 Delivery of drug in the vicinity of site of action. 
 More efficient utilization of active agent. 
 
Disadvantages of controlled drug delivery 
 Dose dumping.   
 Reduced potential for accurate dose adjustment. 
 Need of additional patient education. 
 Stability problem. 
 
Classification of rate controlled drug delivery system2-4 
 Rate controlled drug delivery system 
1. Activation modulated drug delivery system. 
2. Feedback regulated drug delivery system. 
3. Site specific drug delivery. 
Activation modulated drug delivery system 
In this group of Controlled drug delivery system the release of drug molecule from the 
drug delivery system is activated by some physical, chemical or biochemical processes. 
 
 
 
Introduction 1 
  
Department of Pharmaceutics, Madras Medical College Page 4 
 
CLASSIFICATION 
1. Physical means 
a. Osmotic pressure activated drug delivery system 
b. Hydrodynamic pressure activated drug delivery system 
c. Vapour pressure activated drug delivery system 
d. Mechanically activated drug delivery system 
e. Magnetically activated drug delivery system 
f. Sonophoresis activated drug delivery system 
g. Iontophoresis activated drug delivery system 
h. Hydration activated drug delivery system 
2. Chemical means 
a. pH activated drug delivery system 
b. Ion exchange drug delivery system 
c. Hydrolysis activated drug delivery system 
3. Biochemical means 
a. Enzyme activated drug delivery system 
b. Biochemical activated drug delivery system 
OSMOTIC PRESSURE ACTIVATED DRUG DELIVERY SYSTEM 
Osmosis refers to the process of movement of solvent molecules from lower 
concentration to higher concentration across a semipermeable membrane. Osmotically controlled 
oral drug delivery systems utilize osmotic pressure for controlled delivery of active agent. Drug 
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delivery from these systems, to a large extent, is independent of the physiological factors of the 
GIT. These systems can be utilized for systemic as well as targeted delivery of drugs. The release 
of drug from osmotic systems is governed by various formulation factors such as solubility and 
osmotic pressure of the core component, size of the delivery orifice and nature of the rate-
controlling membrane. By optimizing formulation and processing factors, it is possible to 
develop osmotic systems to deliver drugs of diverse nature at a pre-programmed rate. 
An osmotically dispersion formulation comprises of the following (Figure 1.2) 
1. A water permeable membrane forming a part or all the walls of enclosure surrounding. 
2. An activated agent. 
3. An additive known as an osmotically attractant which together exhibit an osmotic pressure. 
                              Drug reservoir         drug delivery orifice     movable partition 
Osmotically salt     Semipermeable membrane                                          
                         Fig. 1.2: Osmotic Drug Delivery System 
 When placed in aqueous environment water is osmotically drawn into the enclosure by 
the combined action of active component and movable partition which distend and swells and 
result in the release of drug from the orifice to the external environment. The rate of drug release 
is modulated by controlling the gradient of osmotic pressure. The intense rate of drug release 
(Q/t) is defined by equation (1) 
Q/t = Pw Am (ps - pc) 
                                                                      ______                ------------------------ (1) 
                                                                        hm 
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Where: 
Pw - Water permeability. 
Am - Effective surface area. 
hm - Thickness of the semipermeable housing. 
(ps - pc) - Difference of osmotic pressure between the drug delivery system with osmotic 
pressure (ps) and environment with osmotic pressure (pc) 
Historic back ground 
The Rose Nelson pump  
In 1955 two Australian Physiologist Rose and Nelson reported the first osmotic pump 
(Figure. 1.3). They were interested in delivery of drugs to the gut of sheep and cattle. 
o A drug chamber with an orifice. 
o A salt chamber with elastic diaphragm containing excess solid salt. 
o A water chamber. 
The drug and water chamber are separated by a rigid semipermeable membrane. The 
difference in osmotic pressure across the membrane moves water from the water chamber into 
salt chamber. The volume of salt chamber increases because of this water flow, which distends 
the latex diaphragm separating salt and drug chamber there by pumping drug out of this device. 
The pumping rate of Rose-Nelson pump is given by the equation (2): 
dm/dt = dv/dt*c ----------------------- (2) 
Where: 
dm/dt - Drug release rate. 
dv/dt  - Volume flow of water into salt chamber. 
c - Concentration of drug into drug chamber. 
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         Water chamber                       Salt chamber                       Drug chamber 
 
Fig. 1.3: Rose Nelson Pump 
Higuchi Leeper pump  
The design of Higuchi Leeper pump (Figure 1.4) represents the first simplified version of 
the Rose Nelson pump made by the Alza Corporation in the early 1970. The benefit of this pump 
over Rose Nelson pump is that it does not have water chamber and the device is activated by 
water imbibed from the surrounding environment. 
 
Fig. 1.4: Higuchi Leeper pump 
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Higuchi- Theeuwes pump 
In the early 1970 Higuchi – Theeuwes developed a similar form of Rose Nelson pump 
(Figure1.5). The semi permeable wall itself act as a rigid outer casing of the pump .The device is 
loaded with drug prior to use. When the device is put in an aqueous environment the release of 
the drug follows a time course set by the salt used in the salt chamber and the permeability of the 
outer membrane casing. 
                            
Fig. 1.5: Higuchi- Theeuwes pump 
Classification of the Oral Osmotic Drug Delivery Systems 
 Oral osmotic drug delivery system can be classified as follows 
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TYPES OF OSMOTIC SYSTEMS AND THEIR MECHANISM 
The design, mechanism and application of various types of osmotic system are shown in 
table 1.1. 
Table 1.1: Different types of osmotic systems - Design, mechanism and uses  
 
Osmotic System 
 
 
Design of Dosage 
Form 
 
 
     Mechanism 
 
 
Applications 
 
Single chamber osmotic pumps 
 
 
Elementary 
Osmotic Pump 
(EOP)  
 
 
Core: API ± 
osmogen.  
Coat: Semi 
permeable 
membrane with 
delivery orifice.  
 
 
The water 
penetrates inside the 
dosage form. This 
results in formation 
of saturated solution 
of drug within the 
core, which is 
dispensed at a 
controlled rate from 
the delivery orifice 
present in the 
membrane.  
 
 
Moderately 
soluble API       
60- 80% constant 
release.  
 
 
Controlled 
porosity osmotic 
pump (CPOP)  
 
 
Core: API ± 
osmogen 
Coat: Semi 
permeable 
membrane 
containing water 
soluble additives  
 
 
Delivery orifice is 
formed by the 
incorporation of a 
leachable 
component.  
 
Once the tablet 
comes in contact 
with aqueous 
environment, water-
soluble additives 
dissolve and lead to 
the formation of a 
micro porous 
membrane.  
 
Water diffuses into 
the core through the 
 
Poorly soluble 
drugs.  
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micro porous 
membrane, creating 
an osmotic gradient.  
 
 Thereby the release 
of drug is controlled 
 
Multi chamber osmotic pumps 
 
Sandwiched 
Osmotic tablets 
(SOTS)  
 
 
Core tablet: 3 
layers.  
Middle layer: push 
layer.2 attached 
layers of API  
Coat: Semi 
permeable 
membrane with two 
side delivery orifice  
 
 
The middle push 
layer swells and 
drug is released 
from delivery 
orifices present on 
two sides of the 
tablet.  
 
 
API release from 
two sides of 
tablets.  
 
 
Push-pull osmotic 
pump (PPOP)  
 
 
Core Tablet: Layer 
1: API ± osmogent 
Layer 2: Polymeric 
osmotic agents 
Coat: Semi 
permeable 
membrane with 
delivery orifice.  
 
 
After coming in 
contact with the 
aqueous 
environment, 
polymeric osmotic 
layer swells and 
pushes the drug 
layer and thus 
releasing drug in 
the form of fine 
dispersion through 
the orifice.  
 
 
For delivery of 
APIs having 
extremes of water 
solubility. 
Modifications can 
be done: - delayed 
push-pull - multi-
layer push- pull - 
push-stick system  
 
 
Controlled-Porosity Osmotic Pump (CPOP) 
The CPOP is a spray-coated or coated tablet with a semi permeable membrane containing 
leachable pore forming agents. They do not have any aperture to release the drugs. Drug release 
is achieved through the pores, which are formed in the semi permeable wall in situ during the 
operation. In this system, the drug after dissolution inside the core is released from the osmotic 
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pump tablet by osmotic pressure and diffusion through pores created by the dissolution of pore 
formers incorporated in the membrane (Figure 1.6). The osmotic pressure is created either by an 
osmogen or by the drug itself or by a tablet component, after water is imbibed across the semi 
permeable membrane. This membrane after formation of pores becomes permeable for both 
water and solutes. A controlled-porosity osmotic wall can be described as having a sponge like 
appearance. The pores can be continuous that have micro porous lamina, interconnected through 
tortuous paths of regular and irregular shapes. Generally, materials (in a concentration range of 
5% to 95%) producing pores with a pore size from 10 Å -100 µm can be used. 
 
Fig. 1.6: CPOP tablet before and after dissolution studies 
Basic components required for CPOP 
a) Drug 
b) Osmogen 
c) Semi permeable membrane 
d) Channeling agents or pore forming agent 
 
Specifications for CPOP 
 The specification for developing CPOP is given in table 1.2. 
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Table 1.2: Specifications for controlled- porosity osmotic pump 
S.No Materials Specifications 
1 Core loading (size) 0.05 mg to 5 g or more (include dosage forms 
for Humans and animals). 
2 Osmotic pressure 
developed by a solution of 
core 
8 to 500atm typically, with commonly 
encountered water soluble drugs and 
excipients. 
3 Core solubility To get continuous uniform release of 90% or 
greater of the initially loaded core mass 
solubility S, to the core mass density, must be 
0.1 or lower. 
Typically it occurs when 10% of the initially 
loaded core mass saturates a volume of external 
fluid equal to the total volume of the initial 
core mass. 
4 Plasticizers and flux 
Regulating agents 
0 to 50, preferably 0.001 to 50 parts per 100 
parts of wall material. 
5 Surfactants 0 to 40, preferably 0.001to 40 parts per 100 
parts of wall material. 
6 Wall thickness 1 to 1000, preferably 20 to 500 µm 
7 Micro porous nature 
 
Pore forming additives 
5 to 95% pores between 10A0 to 100 µm 
diameter. 
0.1 to 60%, preferably 0.1 to 50%, by weight, 
based on the total weight of additive and 
polymer. 
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1. Criteria for selection of a drug: 
i. Short  biological Half-life (2- 6 hrs) 
ii. High potency 
iii. Required for prolonged treatment (Example: Nifedipine, Glipizide, Verapamil and 
Chlorpromazine hydrochloride) 
2. Osmogen 
Polymeric osmogen is mainly used in the fabrication of osmotically controlled drug 
delivery systems and other modified devices for controlled release of relatively insoluble drugs. 
Osmotic pressures for concentrated solution of soluble solutes commonly used in controlled 
release formulations are extremely high, ranging from 30 atmospheric pressure (atm) for sodium 
phosphate up to 500 atm for a lactose-fructose mixture (Table 1.3). These osmotic pressures can 
produce high water flows across semi permeable membrane. 
 
Table 1.3: Osmotic Pressure of Saturated Solutions of Common Pharmaceutical Solutes 
S.No 
 
Compound or mixture 
 
Osmotic Pressure(atm) 
1 Lactose-fructose 500 
2 Dextrose-fructose 450 
3 Sucrose-fructose 430 
4 Mannitol-fructose 415 
5 Sodium chloride 356 
6 Fructose 335 
7 Lactose-sucrose 250 
8 Potassium chloride 245 
9 Lactose-dextrose 225 
10 Mannitol 38 
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3. Semipermeable Membrane (SPM) 
The membrane should be stable to both outside and inside environments of the device. 
The membrane must be sufficiently rigid so as to retain its dimensional integrity during the 
operational lifetime of the device. The membrane should also be relatively impermeable to the 
contents of dispenser so that osmogen is not lost by diffusion across the membrane. The 
membrane must be biocompatible. Some good examples for polymeric materials that form 
membranes are cellulose esters like cellulose acetate, cellulose acetate butyrate, cellulose 
triacetate, ethyl cellulose and Eudragit. 
 
Ideal properties of SPM  
a)   The material must possess sufficient wet strength (10-5 Psi) and wet modules so (10-5    
 Psi) as to retain its dimensional integrity during the operational lifetime of the device. 
b)   The membrane must exhibit sufficient water permeability so as to attain water flux 
 rates   (dv/dt) in the desired range. The water vapour transmission rates can be used to 
 estimate water flux rates. 
c)  The reflection coefficient or “leakiness” of the osmotic agents should approach the 
 limiting value of unity. 
 
4. Channeling agents/ leachable pore forming agents 
These are water-soluble components which play an important role in the controlled drug 
delivery systems. When the dissolution medium comes into contact with the semi permeable 
membrane it dissolves the channeling agent and forms pores on the semi permeable barrier. Then 
the dissolution fluid enters the osmotic system and releases the drug in a controlled manner over 
a long period of time by the process of osmosis. Some examples of channeling agents are 
Polyethylene glycol (PEG) 1450, Mannitol, Bovine serum albumin (BSA), Diethyl phthalate, 
Dibutylphthalate (DBP) and sorbitol. 
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Advantages of oral controlled osmotic drug delivery system (OCODDS) 
1. Provides Zero-order delivery rate. 
2. Delayed or pulsed drug delivery is obtainable with osmotic system. 
3. The delivery rate is significantly greater than that attainable with diffusion based systems 
of comparable size. 
4. In vitro delivery rate can be accurately predicted using mathematical equations, which in 
turn, bears high degree of correlation with in vivo delivery rate. 
5. Delivery rate is independent of pH variations in the environment, including those in the 
gastrointestinal tract (GIT). 
6. Delivery rate is independent of agitation outside, including GI motility. 
7. Release rate from osmotic system is highly predictable and programmable. 
8. Delivery of drug takes place in the solution form ready for absorption, with osmotic 
pump simulating as a liquid dosage form prepared in-situ. 
9. Delivery rate is almost independent of delivery orifice size within limits. 
10. Drugs with widely varying solubility can be incorporated. 
11. The device is relatively simple to fabricate using conventional pharmaceutical 
manufacturing equipment.  
12. Drug release from the osmotically controlled oral drug delivery system exhibits 
significant in vitro-in vivo correlation [IVIVC] within specific limits. 
 
Disadvantages 
1. Drug release from the osmotic systems is affected to some extent by the presence of 
   food. 
2. Retrieval of therapy is not possible in case of unexpected adverse events. 
 
Patents related to Controlled porosity osmotic pump 
 The Patents related to CPOP is given in table 1.4 and the commercially available osmotic 
systems are given in table 1.5. 
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Table1.4: Patents related to Controlled porosity osmotic pump 
S.No. U.S. Patent 
number 
Type of osmotic system 
1 4,968,507 Controlled porosity osmotic pump. 
2 4,880,631 Controlled-porosity osmotic pump of Diltiazem L-maleate. 
3 4,256,108 Micro porous semi permeable laminated osmotic system. 
4 4,160,452 Osmotic system having laminated wall comprising of semi 
permeable lamina and micro porous lamina. 
5 4,340,054 Semi permeable membrane consisting of impregnated micro 
porous membrane. 
6 4,450,198 Semi permeable membrane consisting of a micro porous film 
impregnated with a hydrophilic polymer. 
7 4,946,686 Controlled-porosity solubility modulated osmotic pump for 
delivering of drug having low water solubility. 
8 4,994,273 Controlled-porosity solubility modulated osmotic pump for 
delivering of drug having low water solubility. 
 
Table 1.5: Marketed products of different osmotic systems 
Product 
Name Active ingredient Design Dose 
Acutrim Phenylpropanolamine Elementary pump 75 mg 
Alpress LP Prazosin Push Pull 2.5-5mg 
Cardura XL Doxazosin Push pull 4, 8 mg 
Covera HS Verapamil Push -Pull with time delay 180, 240mg 
Ditropan XL Oxybutynin chloride Push Pull 5, 10 mg 
Dynacirc CR Isradipine Push Pull 5, 10 mg 
Efidac 24 Chlorpheniramine meleate Elementary Pump 4 mg IR, 12 mg CR 
Glucotrol XL Glipizide Push – Pull 5, 10 mg 
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REVIEW OF LITERATURE FOR OSMOTIC DRUG DELIVERY SYSTEMS 
 
1. Shahla Jamzad et al.5 developed a new monolithic matrix system to completely deliver 
Glipizide, a BCS Class II drug in a zero order manner over an extended time period. Two 
approaches were examined using drug in formulations that contain swellable Hydroxyl Propyl 
Methyl Cellulose (HPMC) or erodible Poly Ethylene Oxide (PEO). The interrelationship 
between matrix hydration, erosion and textural properties were determined and analyzed 
under the dissolution test conditions. As a result it was concluded that there was a linear 
release of Glipizide, similar to the profile of the commercial Glucotrol XL. The kinetics of 
drug release was shown to be in accordance with kinetics of hydration/swelling in HPMC-
based formulation, while in PEO system erosion kinetics dominated the release operation. 
 
2. Mothilal et al.6 formulated Osmotic drug delivery system (ODDS) for Metoprolol 
Succinate using different concentrations of mannitol by wet granulation technique. The tablets 
were coated by dip coating with Cellulose acetate and stainless steel drill pins were used to 
make an orifice on the tablets and the orifice diameter was examined using scanning electron 
microscopy (SEM). As a result of in vitro release study it was concluded that rate of drug 
release were found to be increasing with increase in osmogen content and bore size and the 
optimum orifice diameter was identified to be 0.8 mm to give a zero order release. 
 
3. En-Xian Lu et al.7 designed a monolithic osmotic tablet system (MOTS) of Naproxen, a 
water insoluble drug with two orifices in both side surfaces. Gum Arabic was used as an 
osmotic, suspending and expanding agent. Cellulose acetate (CA) was used as semipermeable 
membrane with PEG-400 as a plasticizer. The influences of gum Arabic, PEG-400, membrane 
thickness and orifice size on the Naproxen release profiles were investigated and the optimal 
MOTS was evaluated in different environment media and stirring rates. As a result of this 
study, optimal MOTS was found to be able to deliver Naproxen at a rate of approximately 
zero order up to 12 h , independent on environment media and stirring rate and it was 
concluded that  this MOTS can be used in oral drug- controlled delivery especially for water-
insoluble drug. 
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4. Rashmin Thakor et al.8 developed and evaluated an oral monolithic osmotically 
controlled delivery system for Nifedipine using asymmetric membrane technology. 
Asymmetric membrane is formed by dry process with phase inversion technology using CA 
as the coating material. Higher water influx of this membrane aids in delivery of Nifedipine, 
which is highly water insoluble with low osmotic pressure. The porous structure of the 
membrane was confirmed by SEM. In vitro release studies showed that as the concentration 
of osmotic agent increases, the drug release was also enhanced and independent of external 
agitation and pH of dissolution media. 
 
5. Basani Gavaskar et al.9 formulated elementary osmotic pump tablets (EOPT) of water 
soluble Tramadol HCl by wet granulation method, coated with CA solution containing 
varying amount of DBP and PEG-400. The optimized formulation of Tramadol EOPT was 
obtained by orthogonal designs based on the single factor influence test. It was evident from 
the result that the rate of drug release can be controlled through osmotic pressure of the core, 
the level of pore former and membrane weight with release to be fairly independent of pH and 
hydrodynamic conditions of the body. 
  
6. Javad Shokri et al.10 designed a new type of Swellable Elementary Osmotic Pump 
(SEOP) tablet for efficient delivery of poorly water-soluble/practically insoluble drugs like 
Indomethacin. SEOP tablets were prepared by compressing the mixture of micronized drug 
and excipients into convex tablets. The results showed that the concentration of wetting agent 
in the core formulation was a very important parameter in release pattern of Indomethacin 
from SEOP system. Increasing the amount of wetting agent to an optimum level (60 mg) 
significantly increased the drug release and improved zero order release pattern of 
Indomethacin. Increasing concentration of castor oil (hydrophobic) in the Semipermeable 
Membrane of the device or hydrophilic plasticizer (glycerin) in coating formulation markedly 
increased the lag time and decreased the drug release. 
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7. Longxiao Liu et al.11 developed a method for the preparation of Atenolol MOPT by 
coating the indented core tablet compressed by the punch with a needle. Formulation contains 
sodium chloride as osmotic agent, PEO as suspending agent and ethyl cellulose (EC) was 
employed as semipermeable membrane containing PEG 400 as plasticizer. The formulation 
was optimized by orthogonal design and evaluated by similarity factor (f2). It was evident 
from the result that the indentation size of core tablet hardly affected drug release in the range 
of (1.00–1.14) mm. The optimal osmotic tablet was found to be able to deliver Atenolol at an 
approximately constant rate up to 24 h, independent of both release media and agitation rate. 
  
8. Jin Guan et al.12 developed a novel Famotidine gastric resident osmotic pump tablet 
containing Pharmaceutical iron powder as gas formation and density increasing agent. Central 
composite design response surface methodology was used to investigate the influence of 
factors, like PEO (Mw 1,000,000) content, sodium chloride content, iron powder content and 
weight gain, on the responses including ultimate cumulative release and correlation 
coefficient of drug release profile. A second order polynomial equation was fitted to the data 
and actual response values are in good accordance with the predicted ones. The optimized 
formulation displayed a complete drug delivery and zero order release rate. Gamma 
scintigraphy was selected as the method to monitor in vivo gastric residence time of the 
99mTc labeled system in Beagle dogs.  It was observed that the system can retain in stomach 
for an extended period of 7 h after administration compared with conventional tablets.  
 
REVIEW OF LITERATURE FOR CONTROLLED POROSITY OSMOTIC DRUG 
DELIVERY SYSTEMS 
9. Gaylen M Zentner et al.13 investigated the zero-order release of water soluble, 
Osmotically active agents from tablets coated with controlled porosity walls. The rate of drug 
release was a function of the wall thickness, level of leachable additives incorporated and 
permeability of the polymer component of the walls, the total solubility of the core tablet, the 
drug load and the osmotic pressure difference across the wall. Release was not affected by the 
pH and degree of agitation in the receptor media. 
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10. The release kinetics from controlled porosity osmotic pumps (CPOP) was manipulated by 
Gaylen M Zentner et al.14 The solubility of Diltiazem Hydrochloride was reduced for an 
extended period of 12-14 hours through incorporation of sodium chloride into the core. Other 
Diltiazem Hydrochloride core tablet containing the positively charged anion-exchange resin 
(Poly (4-vinylpyridine)) was prepared. In both instances, in vitro Diltiazem Hydrochloride 
release profile was zero-order and pH-independent. 
  
11. A cellulose acetate latex was modified for use as a microporous coating for osmotic 
devices by Leah E Appel et al.15  Potassium chloride core tablets were coated with a CA 
latex formulation containing a plasticizer, Triacetin and a pore-former, Urea. The results 
indicated that the urea content was the most important variable factor, followed by Triacetin 
content and cure time. Cure temperature was not found to affect the results. The in vitro drug 
release and burst strength results agreed with those predicted by the model.  
 
12. Russell U Nesbitt et al.16 studied the release of water soluble substrates from Aquacoat 
coated pellets through water-filled channels. Each pellet worked like a mini osmotic pump. 
The energy was supplied by the osmotic pressure differences between the internal medium of 
the coated pellets and the external dissolution medium. The drug release was dependent on the 
substrate solubility and the osmotic pressure of the dissolution medium. 
  
13. Kazuto Okimoto et al.17 developed a CPOP tablet for poorly water soluble drug 
(Prednisolone) using a sulfobutyl ether-β-cyclodextrin, (SBE)7m- β -CD or Captisol, which 
acted both as a solubilizer and an osmogen. The results showed that the drug release tablet 
with (SBE) 7m- β -CD was complete. Hence Captisol modified the input rate of Prednisolone 
without affecting oral bioavailability. 
  
14. Rajagopal Kumaravelrajan et al.18 formulated a CPOP system to deliver Nifedipine 
(NP) and Metoprolol (MP) in a controlled manner up to 12h. It was prepared by incorporating 
drugs in the core and coated with various types Poly vinyl pyrrolidone (PVP), PEG-400 and 
HPMC and levels (30, 40 and 50% w/w of polymer) of pore former at a weight                   
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gain of 8, 12 & 15%. This study suggested that drug release from these systems is controlled 
by osmotic pressure as the major mechanism; release pattern followed zero order kinetics and 
independent of environmental medium and the mobility of gastrointestinal tract and it was 
concluded that drug release was directly related to the level of pore former and inversely 
proportional to the membrane weight gain. 
 
15. Sapna N Makhija et al.19 described a CPOP of Pseudoephedrine (half life 5–8 hours) 
containing sodium bicarbonate as osmogen and CA as semi permeable membrane. Different 
channeling agents tried was dibutylsebacate, diethylphthalate, DBP and PEG 400. It was 
found that the rate increased with the amount of osmogen due to increased water uptake. 
 
16. Rajan K Verma et al.20 developed extended release Isosorbide Mononitrate tablets 
based on osmotic technology. Formulation variables like (PVP, PEG-4000, and HPMC) and 
level of pore former (0–55% w/w of polymer), percentage weight gain were found to affect 
the drug release. Release was dependent on membrane weight, level of pore former in the 
membrane, osmotic pressure of the dissolution media and independent of pH and agitational 
intensity. 
 
17.  Pritam Kanagale et al.21 designed an osmotic pump tablet for controlled release of 
Oxybutynin for 24 hours. The osmotic pump contains water-soluble pore-former in the 
semipermeable membrane (CA) which dissolves after coming in contact with water, resulting 
in an in situ formation of a microporous structure. This osmotic pump was found to deliver 
Oxybutynin at a zero order rate for upto 20 hours.  
 
18. Controlled porosity osmotic pump tablets of Glipizide were developed by       
Mahalaxmi R et al.22  The effect of level of wicking agent, solubilizing agent, pore former 
and membrane weight gain on in vitro release rate were studied. Drug release was directly 
proportional to the pore former (sorbitol), inversely proportional to weight gain of the 
membrane, independent of pH and agitational intensity but dependent on osmotic pressure of 
the release media.  
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19. Anil Chaudhary et al.23 developed microporous bilayer osmotic tablet bearing 
Dicyclomine Hydrochloride and Diclofenac Potassium using a new oral drug delivery system 
for colon targeting. The tablets were coated with micro-porous semipermeable membrane and 
enteric polymer.  The colon-specific biodegradation of pectin could form in situ delivery 
pores for drug release. The effect of formulation variables like inclusion of osmogen, amount 
of HPMC and SCMC in core, amount of pore former in SPM was studied. In vitro dissolution 
results indicated that system showed acid-resistant, timed release and was able to deliver drug 
at an approximate zero order up to 24 h.  
 
20. Prakash Rao B et al. 24 formulated a swellable controlled porosity osmotic pump tablet 
of Theophylline. The core tablets were spray coated with ethyl cellulose (EC) solution 
containing varying amounts of PEG 400 and plasdone. The results indicated that the release 
rate of Theophylline was directly proportional to the levels of osmotic agent, solubilizing 
agent and pore former in the tablet core and the membrane respectively. The preparation was 
facilitated by coating the core tablet with pore forming agent, thus eliminating the need for the 
more expensive laser drilling. 
 
21. Ji-Eon Kim et al.25 studied the effect of various pore formers on the controlled release of 
an antibacterial agent from a polymeric device. Cefadroxil was chosen as the model antibiotic 
and was incorporated into a polyurethane matrix by the solvent-casting method. PEG 1450 or 
D-mannitol, or bovine serum albumin (BSA) was used as a pore former. The morphological 
changes in the matrices before and after release studies were investigated by SEM. Changing 
the weight fraction and particle size of the pore formers/drug mixtures could control the 
release of Cefadroxil from the matrix. The release rate of Cefadroxil increased as the loading 
dose of the pore former increased (15<20<25%). 
 
22. Rajan K Verma et al.26 studied the formulation aspects in the development of 
osmotically controlled oral drug delivery systems. In this review, different types of oral 
osmotic systems, various factors governing drug release from these systems and critical 
formulation factors were discussed. 
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23. Sudeesh Edavalath et al.27 designed a porous osmotic pump tablet of Diclofenac sodium 
using D-Optimal study design and numerical optimization method was used to find out the 
best formulation. Osmotic agent sodium chloride and pore former PEG-400 were considered 
as independent variables. The influence of pH and agitational intensity on drug release was 
studied. As a result of D-Optimal and ANOVA study it was concluded that osmotic agent and 
pore former have significant effect on the drug release upto 24hrs.  
 
24. Hui Liu et al.28 developed a microbially triggered colon-targeted osmotic pump of 
Budesonide based on both the gelable property at acid conditions and colon-specific 
biodegradation of chitosan. The effects of different formulation variables were studied to 
select the optimal formulation. From the study it was concluded that Budesonide release from 
the developed formulation was directly proportional to the initial level of pore former, but 
inversely related to level of pH modifier (citric acid) which affected the viscosity of chitosan 
solution, resulting in the change of osmotic pressure in the core tablets. The amount of 
chitosan in core formulation had a profound effect on the amount of drug release. 
 
25. Farheen F et al.29 developed a microbially triggered colon-targeted osmotic tablets of 
Prednisolone using different polymers like chitosan, xanthan gum and pectin by wet 
granulation method and coated with an inner semi permeable layer of EC with chitosan as 
pore forming agents and an outer enteric layer of Eudragit L 100-55. The in vitro dissolution 
study indicated that system showed acid-resistant, timed release and was able to deliver drug 
at an approximate zero order up to 18h. The release was influenced by the type and amount of 
polymer and the percentage of chitosan in SPM and it was concluded that among the different 
polymers used, chitosan was found to be more suitable for colon targeting.  
 
REVIEW OF LITERATURE FOR USING SOLUBILITY ENHANCERS 
26. Meiying Ning et al.30 obtained a method for the preparation of Vinpocetine(VIN) 
elementary osmotic pump tablet by adding organic acid additives to increase VIN solubility. 
From the in vitro and in vivo release study it was concluded that the VIN dissolution was 
increased with increasing the amount of citric acid. 
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27. Deelip Derle et al.31developed numerous approaches for solubility enhancement of BCS 
class II drugs. Various particle engineering processes like super critical fluid technology, 
cryogenic technology, nanomilling, evaporative precipitation into aqueous solution, melt   
sono crystallization and cryo‐vacuum etc., were developed based on the drug properties and 
requirement of nanoparticles characters. From the study it was concluded that the use of these 
processes has improved in vitro dissolution rates and in vivo bioavailability of many poorly 
water soluble drugs.  
 
28. Kapoor Devesh et al.32 used solubility enhancer SLS, HPMC and osmogen (mannitol) to 
enhance the solubility and osmotic pressure in CPOP of Valsartan. As a result of the study, 
the release of Valsartan increased with increasing the amount of SLS, HPMC and mannitol. 
 
29. Kumar P et al.33 investigated a method to increase the solubility of Naproxen(NS) in 
elementary osmotic pump by using different solubility enhancers. The findings of this study 
concluded that the rate and extent of NS release were found to be dependent on different 
osmogen, SLS, and sodium bicarbonate in the core formulation of Elementary Osmotic Pump 
and independent of agitational intensity of release medium. 
 
30. Roger A Rajewski et al.34 studied the membrane controlling factors responsible for drug 
release from a CPOP tablet that utilizes sulfobutyl ether cyclodextrin, (SBE)7m β -CD, both as 
solubilizing agent and osmogen. The release rate of Chlorpromazine from OPTs containing 
(SBE)
 7m β -CD increased with increasing amounts of micronized lactose and decreasing 
amounts of triethyl citrate. The effect of lactose particle size in the membrane on drug release 
was studied. 
 
31. Roger A Rajewski et al.35  investigated the application of CPOP tablet  utilizing (SBE)7m 
β CD both as a solubilizer and an osmotic agent for drugs with varying physical properties. 
CPOP tablets utilizing (SBE)
 7m β CD were prepared for five poorly soluble drugs such as 
Prednisolone, Estradiol, Naproxen, Indomethacin and Chlorpromazine and for two highly 
water soluble drugs such as Diltiazem Hydrochloride and Salbutamol Sulfate.                         
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It was found that for the soluble drugs (SBE)
 7m β -CD acts primarily as an osmotic and an 
OPT control agent. Significantly, (SBE)
 7m β CD not only enhances the delivery of poorly 
soluble drugs from OPTs but acts as a controlling excipient for soluble drugs such that the 
release rate, corrected for tablet surface area, of both poorly soluble and soluble drugs are 
similar. 
 
32. Stella J et al.36 developed CPOP system for poorly watersoluble drugs such as 
Testosterone using sulfobutyl ether -cyclodextrin (SBE)7mβ CD sodium salt, which can act as 
both a solublizing agent and an osmogen. The effect of   (SBE)
 7mβ -CD as the solubilizing 
and osmotic pump agent was compared with Hydroxypropyl- β -cyclodextrin (HP-β CD), a 
neutral cyclodextrin, and a sugar mixture (osmogen only). Testosterone release from the 
device was significantly faster with (SBE) 7m β CD than with HP β CD or the sugar mixture. It 
was concluded that (SBE) 7m β CD provides novel properties for the development of CPOP 
tablet for poorly soluble drugs. 
 
33. Gaylen M et al.37 studied the application of either solubility or resin-modulated method 
to effectively manipulate drug release kinetics from CPOPs. These solubility-modulated 
devices administered to dogs release Diltiazem Hydrochloride with similar in vivo / in vitro 
kinetics. These approaches may be applicable to extend osmotic pump technology to drugs 
with intrinsic water solubility that is too high or low for conventional osmotic pump 
formulation. 
 
34. Philip AK et al.38  developed an asymmetric membrane capsular system, formed in situ, 
for poorly water soluble drug, Ketoprofen and evaluated it by both in vitro and in vivo 
methods for osmotic and controlled release of the drug. Membrane characterization by SEM 
showed an outer dense region with less pores and an inner porous region for the prepared 
asymmetric membrane. 
 
35. Longxiao Liu et al.39 developed a  method for the preparation of monolithic osmotic 
pump tablet was obtained by modulating atenolol solubility with acid and employed      
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sodium chloride as osmotic agent and polyvinyl pyrrolidone as retardant agent. EC was 
employed as SPM containing PEG 400 as plasticizer. The formulation of Atenolol MOTS was 
optimized by orthogonal design and evaluated by similarity factor (f2). The influences of 
tartaric acid, PVP, sodium chloride and membrane thickness on drug release profile were 
investigated to determine significant associations of factors based on the L orthogonal design. 
From the study it was concluded that the optimal monolithic osmotic pump tablet was able to 
deliver Atenolol at the rate of approximate zero-order up to 24 h, independent of release 
media and agitation rate.  
 
REVIEW OF LITERATURE FOR LORNOXICAM 
36. Yassin El-Said Hamza et al.40 formulated an extended release matrix tablets of 
Lornoxicam (LOX) using different grades of HPMC K4M, K15M, K100M as a matrix 
former. Matrix tablets were prepared by direct compression and the effect of two basic pH-
modifiers, sodium bicarbonate and magnesium oxide, on the release characteristics of 
Lornoxicam from the prepared hydrophilic matrices was investigated. All the matrices 
prepared using different viscosity grades of HPMC employed at concentrations of 25% and 
30% showed comparable release profiles. Results obtained demonstrated that tablets 
composed of 15% of HPMC K15M and 10% sodium bicarbonate, possessed acceptable 
physical properties and elicited the required in vitro release pattern. 
 
37. Hariprasanna RC et al.41 prepared bi-layer tablet of Lornoxicam (LOX) for the 
effective treatment of arthiritis. The tablets were formulated as immediate release layer and 
sustained release layer using hydrophilic matrix polymer sodium alginate by wet granulation 
method. It is evident from the results that a matrix tablet prepared with sodium alginate and 
binding agent (PVP 4% w/v) is a better system for twice -daily sustained release of a highly 
water-insoluble drug like LOX. 
 
38. Ganesh N S et al.42 formulated chronomodulated drug delivery system of Lornoxicam to 
prolong its duration of action and thus reduce the frequency of usage and to minimize its 
irritant effect on the stomach. Nine formulations of Microspheres of LOX were formulated at 
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various drug: polymer ratio by emulsification, suspension polymerization and emulsification 
solvent evaporation techniques by using polymers like Gelatin, SCMC and Chitosan 
respectively. From the in vitro release study it was concluded that natural polymers like 
Gelatin, SCMC and Chitosan can be successfully used for the chronomodulated drug delivery 
system of LOX for the effective treatment of arthritis, where morning stiffness is more 
prominent. 
 
39. Metker Vishal et al.43 prepared mouth  dissolving  tablets  of Lornoxicam by  wet  
granulation technique  using  KYRON  T-314  as superdisintegrant and menthol as subliming 
agent. It  can  be  concluded  that  sublimation method  showed  better  disintegration  and  
drug  release. The  prepared  tablets  using  KYRON  T-314 disintegrate  within  few  seconds  
without  need  of water;  thereby  enhancing  the  absorption  leading  to its  increased  
bioavailability.  
 
40. Phani Kumar  et al.44 formulated Lornoxicam matrix tablets by wet granulation method 
by using 10%, 20%, 30%  and 40% Tamarind Seed Polysaccharide (TSP) as a natural binding 
agent and its optimized batch was compared with maximum ratio of various binders (HPMC 
K4M, SCMC, Guar Gum). After 24 hours release study tablets with 20% TSP binder showed 
maximum drug release (99.45%) and tablets with 40% TSP binder showed minimum drug 
release (62.55%). It was concluded that matrix tablet containing 20% TSP binder release the 
drug which follows Zero order kinetics via, swelling, diffusion and erosion. 
 
41. Fawzia Habib et al.45 formulated  mucoadhesive buccal patches of Lornoxicam  using 
different polymers including, Hydroxyethyl cellulose (HEC), Hydroxypropyl cellulose (HPC), 
HPMC, chitosan, polyvinyl alcohol (PVA), gelatin, sodium alginate and  SCMC. The            
in vitro release study and drug permeation study was conducted. It was concluded that 
Gelatin, Sodium alginate and SCMC patches showed the highest drug release rate of the drug 
in vitro and more drug permeation through rabbit buccal mucosa than other formulations.  
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42. Gülgün Yener et al.46 prepared transdermal film formulations for Meloxicam (MX) and 
Lornoxicam using different polymers. From the study it was concluded that HPMC as a 
polymer and propylene glycol (PG) as a plasticizer provided best release profile. In vivo 
studies on rats employed for the assessment of anti-inflammatory effect indicated that MX 
and LOX transdermal patches gave satisfactory results regarding the edema inhibition. All 
those results were supported by ex vivo penetration study in that effects of log P, molecular 
weight, pKa and solubility constraint of the relevant drugs were considered. 
 
43. Sheth SK et al.47 developed a taste masked oral disintegrating tablet of poorly soluble 
Lornoxicam by direct compression technique with β cyclodextrin complexes using various 
super disintegrants. Results suggested that formulation containing complexing drug with BCD 
in 1:2 ratio, and with 7.5% of croscarmellose sodium masked bitter taste of drug and satisfy 
all the criteria of oral disintegrating tablet. 
 
44. Kavitha K et al.48 developed and evaluated matrix type transdermal patches of 
Lornoxicam using different polymers like HPMC and EC in different ratios by solvent 
evaporation technique. From the study it was concluded that formulation with combination of 
polymers (1:1) showed maximum release in 24 hours. 
 
45. Vinod Dube et al.49 developed sustained release matrix formulation of Lornoxicam 
targeted to colon using different concentration of HPMC and EC by direct compression 
method. From the study it was observed that 10% of each polymer in combination was able to 
produce desire formulation which releases more than 90% of drug in 10 hours. 
 
46. Yassin El-Said Hamza et al.50 developed new directly compressed, double-layer tablets 
(DLTs) of Lornoxicam. Each of the proposed DLTs is composed of a fast-release layer and a 
sustained release layer, anticipating rapid drug release that starts in the stomach to rapidly 
alleviate the symptoms and continues in the intestine to maintain protracted analgesic effect. 
An amorphous, freeze-dried inclusion complex of Lornoxicam with Hydroxypropyl-β-
cyclodextrin, present in 1:2 (drug/cyclodextrin) molar ratio was employed in the                 
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fast-release layer to enhance the dissolution of LOX in the stomach. Xanthan gum (XG), a 
hydrophilic matrix-forming agent, was integrated in the sustained-release layer. DLTs 
composed of sustained-release layer (40% XG) to fast-release layer in 2:1 weight ratio and 
those composed of sustained-release layer (50%XG) to fast-release layer in 1:1 weight ratio 
showed the desired release profile.  
 
REVIEW OF LITERATURE FOR THE ANALYSIS OF LORNOXICAM 
47. Bhupendra Singh et al.51 developed a simple spectrophotometric method for the 
determination of Lornoxicam in pharmaceutical tablet dosage form. From these characteristics 
of the proposed method, it was found that LOX follow linearity within the concentration 
range of 1-20mcg and it was found that the percentage recovery values of pure drug from the 
analyzed solution of formulation were in between 95.01 to 124 which indicates that the 
proposed method is accurate and also reveals that the commonly use excipients and additives 
in the pharmaceutical formulation were not interfering in the proposed method.               
Hence, concluded that this method can be used for the routine determination of LOX in pure 
and pharmaceutical formulation. 
 
48. Kondawar MS et al.52 developed a new simple, accurate, precise and economic 
spectrophotometric methods in UV/VIS region for the determination of Paracetamol (PARA) 
and LOX in bulk and tablet formulations. The developed method was validated in terms of 
parameters like accuracy, precision, linearity, and limit of detection and limit of quantitation 
in this method, the overlain spectra of drugs showed the λmax of 235 nm and 376 nm for 
PARA and LOX respectively. The percent recoveries were found near to 100% for both the 
drugs showed the absence of interference indicating that the method is precise and 
reproducible. The method was found to be precise as % RSD for precision were < 2. Hence 
the method was found to be economic, simple and rapid, and can be employed for routine 
analysis in quality control laboratories. 
 
49. Atul R Bendale et al.53 developed a new spectrometric method for Lornoxicam 
estimation in tablet dosage form with good accuracy, simplicity and precision. From the study 
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it was concluded that Lornoxicam obeyed linearity in the concentration range of 5-30mcg and 
the proposed method was statistically validated. 
 
50. Nilesh Jain et al.54 developed a spectrometric method for simultaneous estimation of 
Lornoxicam and Paracetamol in tablet dosage form. The methods employed were Absorbance 
ratio method and simultaneous estimation method. These methods were developed based on 
the simultaneous estimation of drugs in a binary mixture without previous separation. From 
the study it was concluded that LOX and PARA obeys Beer’s law in the concentration range 
of 8-40mcg/ml and 10-50mcg/ml respectively. Thus the proposed method was validated and 
successfully applied for simultaneous determination of LOX and PARA in tablet dosage form.  
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AIM OF THE WORK 
  Lornoxicam (LOX) is a mainstay Non Steroidal Anti Inflammatory Drug 
(NSAID) for the treatment of inflammatory diseases like Rheumatoid Arthritis (RA) and 
Osteoarthritis (OA). But this drug has shorter half life (3-4 hours) and induces side effects 
when used for long term. The aim of the present study is 
1. To formulate controlled porosity osmotic tablets of LOX using mannitol as osmogen. 
2. To increase the solubility of LOX using tromethamine as solubility modifier and SLS as 
wicking agent. 
3. To release LOX in a controlled manner osmotically with cellulose acetate coating along 
with sorbitol as a pore former. 
  The main objective of the study is to produce controlled release of LOX for the 
pain management of RA and OA and to improve the efficacy and patient compliance.  
PLAN OF THE WORK 
 The present study was designed and planned as follows: 
1. Preformulation studies 
 Physical compatibility studies. 
 Fourier Transform InfraRed Spectroscopy (FTIR) study- Identification and 
Compatibility of drug and excipients. 
2. Standard curve for LOX. 
3. Preformulation studies of drug, blends and granules. 
4. Formulation and development. 
 Formulation of LOX core tablets using mannitol as Osmogen. 
 Controlled porosity osmotic coating of LOX using sorbitol as pore former. 
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5. Evaluation of Coated and Uncoated tablets. 
 Physical characteristics 
• Description 
• Uniformity of weight  
• Diameter and thickness 
• Hardness   
 Friability  
 Drug content 
 Uniformity of content 
 In vitro release study of  tablets 
 Evaluation of optimized formulation 
• Effect of agitation speed on drug release 
• Effect of osmotic pressure on drug release 
• Effect of pH on drug release 
 Evaluation of release kinetics of optimized formulation 
 Stability of optimized formulation as per ICH guidelines 
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RATIONALE OF THE STUDY  
 Arthritis is a form of joint disorder that involves inflammation of one or more 
joints. There are over 100 different forms of arthritis. The most common form, Osteoarthritis 
(degenerative joint disease) is a result of trauma to the joint, infection of the joint or age. Other 
arthritis forms are Rheumatoid Arthritis, Psoriatic Arthritis and related. The major complaint by 
individuals who have arthritis is joint pain. Pain is often constant and may be localized to the 
joint affected. The pain from arthritis is due to inflammation that occurs around the joint, damage 
to the joint from disease, daily wear and tear of joint, muscle strains caused by forceful 
movements against stiff, painful joints and fatigue.55, 56  
RATIONALE FOR SELECTION OF THE DRUG 
 NSAIDs are a large class of medications used to treat arthritis, pain and inflammation. 
There are three categories of NSAIDs: Salicylates (aspirin), the traditional NSAIDs and        
Cyclo Oxygenase enzyme (COX-2) selective inhibitors. 
LOX is a member of the oxicam group of NSAIDs. Oxicam have potent anti 
inflammatory and analgesic effects, but their use is associated with a high risk of GI adverse 
effects. LOX combines the high therapeutic potency of oxicam with an improved GI toxicity 
profile as compared to Naproxen. The clinical trials published so far clearly documents the 
efficacy of LOX as a potent analgesic with excellent anti inflammatory properties in a range of 
painful and/or inflammatory conditions, including postoperative pain and RA.57 
 But LOX has shorter half life, which makes the development of controlled release 
formulations extremely advantageous. However, due to its weak acidic nature, its release from 
extended release delivery system is limited to the lower GIT which consequently leads to a 
delayed onset of its analgesic action. This affects the therapeutic efficacy of drug. Therefore it is 
preferable to incorporate solublizing agents and develop a method to deliver the drug in a 
controlled manner. So that the frequency of dosing and dose size can be minimized.40 
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RATIONALE FOR THE SELECTION OF DOSAGE FORM 4 
 The aim of the study is to formulate controlled porosity osmotic tablets. Basic pH 
modifier (solubility modifier) Tromethamine, wicking agent SLS were incorporated into the core 
tablet to create basic environmental pH inside the tablets, which provides complete drug release 
that starts in the stomach to rapidly alleviate the painful symptoms and continue in the intestine 
to maintain protracted analgesic effect. 
 The core tablet is coated with cellulose acetate, a semi permeable membrane with 
sorbitol as pore forming agent. In this controlled porosity system, the drug, after dissolution 
inside the core, is released from the osmotic tablet by hydrostatic pressure and diffusion through 
pores created by the dissolution of pore formers incorporated in the membrane (Figure 4.1). This 
membrane after formation of pores becomes permeable for both water and solutes. 2, 3  
A controlled porosity osmotic wall formed will release the drug in a controlled manner 
for a period of 24 hours and thus the dosing frequency is reduced. 
 
Fig. 4.1: Controlled porosity osmotic tablet 
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INFLAMMATION 58-63 
 Inflammation is part of the complex biological response of vascular tissues to harmful 
stimuli such as pathogens, damaged cells, or irritants. Inflammation is a process by which the 
body’s white blood cells and chemicals protect us from infection and foreign substances such as 
bacteria and viruses. 
Diseases Associated With Inflammation 
Some but not all types of arthritis are the results of misdirected inflammation. Arthritis is 
a general term that describes inflammation in joints. Some types of arthritis associated with 
inflammation include: 
 Rheumatoid arthritis (RA) 
 Shoulder tendinitis or bursitis 
 Gouty arthritis 
 Polymyalgia rheumatica 
Other painful conditions of the joints and musculoskeletal system that are not associated 
with inflammation include osteoarthritis, fibromyalgia, muscular low back pain and muscular 
neck pain. 
Arthritis 
 Arthritis is a chronic degenerative disease that affects the joints of the body. 
Arthritis Types 
• Childhood Arthritis 
• Fibromyalgia 
• Gout 
• Osteoarthritis (OA) 
• Rheumatoid Arthritis 
• Systemic lupus erythematosus (SLE or lupus) 
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A. RHEUMATOID ARTHRITIS 
 RA is a chronic (long-standing) joint disease that damages the joints of the body. The 
damage is caused by inflammation of the joint lining tissue. Inflammation is normally a response 
by the body's immune system to "assaults" such as infections, wounds and foreign objects. In 
RA, the inflammation is misdirected to attack the joints.  
Background 
RA is a chronic inflammatory polyarthritis. 
The natural history of RA varies considerably with at least three possible disease courses. 
1. Monocyclic: Have one episode which ends within 2-5 years of initial diagnosis and did 
not reoccur. This may result from early diagnosis and aggressive treatment. 
2. Polycyclic: The levels of disease activity fluctuate over the course of  condition 
3. Progressive: RA continues to increase in severity and is unremitting. 
 
Pathophysiology 
 Cells that play major role in the pathophysiology of the disease are CD4 T cells, 
fibroblasts, mononuclear phagocytes and osteoclasts. On the other hand, other cells like              
B lymphocytes give rise to auto antibodies like rheumatoid factors. The pathophysiology of 
rheumatoid arthritis is mediated by an inter-related network of cytokines, proteolytic enzymes 
and prostanoids. IL-1, TNF-alpha, etc. are proinflammatory cytokines and are the central 
mediators in the disease.  
The pathogenesis of RA is a complex phenomenon and includes synovial cell 
proliferation, fibrosis, pannus formation and bone and cartilage erosion. 
RA patients show abnormal production of certain inflammatory mediators like cytokines 
and chemokines of numerous types, tumor necrosis factor alpha (TNF-alpha), interleukin-1     
(IL-1), IL-6, IL-8, transforming growth factor beta (TGF-beta), fibroblast growth factor (FGF) 
and platelet-derived growth factor (PDGF). 
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Stages of Development in Rheumatoid Arthritis 
Stage I:         - Synovial Membrane becomes hyperemic and edematous with foci of infiltrating 
small lymphocytes. (Synovitis) 
          - Effussions of joint with high cell count (5,000 to 60,000 per mm3). 
          - X-rays show no destructive changes, but soft tissue swelling or osteoporosis. 
Stage II:       - Proliferation of inflammed synovial tissue and its growth into joint cavity              
                      - Narrowing of joint due to loss of articular cartilage; 
 Stage III:    - Pannus of Synovium; 
                     -  X-rays show extensive cartilage loss, erosions around the margins of joint. 
 Stage IV:     - End stage of disease 
                      - Subsiding of inflammatory process. 
                     -  Fibrous or bony ankylosing of joint will end its functional life; 
                      - Subcutaneous Nodules associated with severe disease. 
 
 
Fig. 5.1: Normal Joint and Rheumatoid Arthritis Joint 
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Incidence and Prevalence 
 Approximately 2.1 million people in the United States and about 1 to 2% of the world's 
population is affected by RA. About 75% of RA patients are women. Typically disease onset 
occurs between 30 and 60 years of age 
Etiology 
 The exact cause of rheumatoid arthritis is still unknown. It is believed that it results from 
genetic as well as environmental triggers. The most significant inflammatory agents are tumor 
necrosis factor and interleukin-1. These are believed to be the triggers for the process of joint 
destruction in RA. Therefore treatment for the disease involves blocking of cytokines to reduce 
inflammation and joint damage. 
Risk Factors 
1. Non Modifiable Risk Factors 
A. Socio-demographics  
The incidence of RA is typically two to three times higher in women than men. In both 
women and men the onset is highest among in the age of sixty. 
B. Genetics 
There is longstanding evidence that specific HLA class II genotypes are associated with 
increase risk.   
 
2. Modifiable Risk Factors 
A.Smoking 
             Among the risk factors, the strongest and most consistent evidence is smoking.  A 
history of smoking is associated with a modest to moderate (1.3 to 2.4 times) risk of RA onset 
and is strongest among people with ACPA-positive (anti-citrullinated protein/peptide 
antibodies), a marker of auto-immune activity. 
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B. Reproductive and breastfeeding history 
Hormones related to reproduction have been studied extensively as potential risk factors for RA: 
1. Oral contraceptives: Studies found that women who had ever used OCs had a modest to 
moderate decrease in risk of RA. 
2. Hormone replacement therapy: There is mixed evidence of an association between HRT 
and RA onset. 
3. Live birth history: Studies have found that women who have never had a live birth have a 
slight to moderately increased risk of RA. 
4. Breastfeeding: Recent studies found that RA is less common among women who 
breastfeed.  
5. Menstrual history: Studies have observed that women with irregular menses or a truncated 
menstrual history have an increased risk of RA.  
 
Signs and Symptoms 
Stiffness, Inflammation, Swelling, Nodules, Pain, Malaise, Fever, Fatigue, Loss of 
appetite, Weight loss, Myalgia, Weakness.  
TREATMENT 
Nondrug approaches 
 Physical therapy helps in increasing the muscle strength and reducing pain. 
 Hydrotherapy involves exercising or relaxing in warm water. . 
 Relaxation therapy teaches techniques for releasing muscle tension, which helps 
relieve pain. 
 Both heat and cold treatments can relieve pain and reduce inflammation. Heat can be 
applied by ultrasound, microwaves, warm wax, or moist compresses. 
 Prosorba column is a medical device that filters antibodies linked to rheumatoid 
arthritis out of the blood. This is used only for severe RA. 
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Drug approaches. 
Rheumatoid arthritis was treated with a stepwise approach starting with NSAIDs and 
progressing through more potent drugs such as glucocorticoids, disease-modifying anti 
rheumatic drugs (DMARDs) and biologic response modifiers. 
NSAIDs  
• COX-2 inhibitors: These agents block only the COX-2 enzyme and are referred to as 
selective NSAIDs. They have fewer side effects than the other NSAIDs. 
Example: Celecoxib 
• Nonselective NSAIDs: These drugs block both COX-1 and COX-2 enzyme. Example: 
 Ibuprofen, Ketoprofen , Naproxen, Lornoxicam and Diclofenac. 
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B. OSTEOARTHRITIS 
Osteoarthritis is a disease characterized by degeneration of cartilage and its underlying 
bone within a joint as well as bony overgrowth. The breakdown of these tissues eventually leads 
to pain and joint stiffness. The joints most commonly affected are the knees, hips and those in 
the hands and spine.  
 
 Background 
 Also known as degenerative joint disease. 
 Most common form of arthritis. 
 Classified as: Idiopathic (localized or generalized) or Secondary (traumatic, 
congenital, metabolic/endocrine/neuropathic and other medical causes). 
 Characterized by focal and progressive loss of hyaline cartilage of joints, 
underlying bony changes. 
 
Stages of Osteoarthritis  
 There are several stages of osteoarthritis: 
• Cartilage loses elasticity and is more easily damaged by injury or use. 
• Wear of cartilage causes changes to underlying bone. The bone thickens and cysts may 
occur under the cartilage. Bony growths, called spurs or osteophytes develop near the end 
of the bone at the affected joint. 
• Bits of bone or cartilage float loosely in the joint space. 
• The joint lining or the Synovium becomes inflamed due to cartilage breakdown 
producing cytokines and enzymes that further damage the cartilage. 
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Fig. 5.2: Normal and Osteoarthritis Joint 
Pathophysiology  
 Cytokines and growth factors play an important role in the pathophysiology of OA 
 Proinflammatory cytokines like TNF- α and IL-1 are believed to play a pivotal role in the 
initiation and development of the disease process 
 Anti inflammatory cytokines like IL-4, IL-10, IL-13 are found in increased levels in OA 
synovial fluid. 
 Prevalence 
 OA affects 13.9% of adults aged 25 and older and 33.6% of those aged 65+  
Incidence 
Incidence rates increased with age.  
Women had higher rates than men, especially after age 50.  
o Men have 45% lower incident risk of knee OA and 36% reduced risk of hip OA than 
women.  
o Prevalent knee OA but not hip or hand OA is significantly more severe in women 
compared to men.  
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Causes 
Endocrine: People with diabetes may prone to OA. Other endocrine problems 
include acromegaly, hypothyroidism, hyperparathyroidism and obesity.  
Post traumatic: Traumatic causes can be divided into macrotrauma or microtrauma. 
Macrotrauma is an injury to the joint such as a bone break causing the bones to line up 
improperly, lose stability, or damage cartilage. Microtrauma may occur over time like 
repetitive movements or the overuse noted in several occupations.  
Inflammatory joint diseases: This includes infected joints, chronic gouty arthritis and 
rheumatoid disease.  
Metabolic: Diseases causing errors of metabolism like Paget's disease and Wilson 
disease may cause osteoarthritis. 
Congenital or developmental: Abnormal anatomy such as unequal leg length may be a 
cause of osteoarthritis.  
Genetic: A genetic defect may promote breakdown of the protective architecture of 
cartilage. Examples include collagen disturbances such as Ehlers-Danlos syndrome.   
Risk Factors 
• Modifiable risk factors 
 Excess body mass. 
 Joint injury. 
 Occupation (due to excessive mechanical stress: hard labor, heavy lifting, knee 
bending, repetitive motion). 
 Structural malalignment, muscle weakness. 
 
• Non-modifiable risk Factors 
 Gender (women higher risk). 
 Age (increases with age and levels around age 75). 
 Race (some Asian populations have lower risk). 
 Genetic predisposition. 
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• Other possible risk factors 
 Estrogen deficiency. 
 Osteoporosis. 
 Vitamins C, E and D – equivocal reports. 
 C-reactive protein (increased risk with higher levels). 
Signs and symptoms 
 Pain, inflammation and swelling in the joint, joint stiffness especially upon waking, 
gradual loss of flexibility in the joint, appearance of small bumps in the affected joint. 
TREATMENT 
Non Medication: Self-Care at Home 
     Lifestyle changes may delay or limit osteoarthritis symptoms. 
 Diet: Antioxidant vitamins C and E may provide some protection. Vitamin D and 
calcium are recommended for strong bones. The recommended daily dose of 
calcium is 1000-1200 mg and for vitamin D is 400 IU per day. 
 Heat: Application of Hot soaks and warm wax (paraffin) may relieve pain.  
 Orthoses: These assistive devices are used to improve function of moveable parts 
of the body or to support, align, prevent, or correct deformities. Splints or braces 
help with joint alignment and weight redistribution. Other examples include 
walkers, crutches or canes, and orthopedic footwear. 
 Weight loss and Exercise  
Medications 
Initially, simple over-the-counter pain relievers such as acetaminophen are 
recommended followed by NSAIDs.  A new generation of prescription NSAIDs are the     
COX-2 inhibitors.  
Nonselective NSAIDs: These drugs block both COX-1 and COX-2. They 
include Ibuprofen, Ketoprofen , Naproxen, Lornoxicam and Diclofenac. 
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LORNOXICAM 55-60 
 Lornoxicam (chlortenoxicam) is a potent inhibitor of both COX-1 and COX-2 enzymes. 
It is a new NSAID of the oxicam class with analgesic, anti-inflammatory and antipyretic 
properties. It differs from other oxicam compounds in its potent inhibition of prostaglandin 
biosynthesis, a property that explains the particularly pronounced efficacy of the drug. 
PHYSIOCHEMICAL PROPERTIES 
Structure 
 
Molecular Formula  : C13H10ClN3O4S2 
Molecular weight : 371.819 
Chemical name:  :2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide,6-chloro-4-hydroxy-2-                  
methyl-N-2-pyridinyl-, 1,1-dioxide 
CAS Number  : 70374-39-9 
Category  : Analgesic, antipyretic and anti-inflammatory agent 
Description   : A yellow crystalline powder 
Solubility  : Slightly soluble in chloroform and 0.1mol/L NaOH and very slightly 
  soluble in methanol and acetonitrile and hardly soluble in water. 
Storage   : Store at room temperature (15°-23°C). 
Melting point  : 225° -230°C  
 
PHARMACOKINETICS 
 
Absorption 
  LOX is absorbed rapidly and completely from the GI tract. Peak plasma concentration is 
obtained within 1-2 hours after oral administration and 25 min after Intramuscular injection. 
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Distribution 
            Lornoxicam has 99% plasma protein binding. LOX and its metabolites bind extensively 
to plasma albumin and it readily penetrates into synovial fluid, the proposed site of action in 
chronic inflammatory arthropathies. 
Metabolism 
LOX is metabolized completely by Cytochrome P2C9 with the principal metabolite being 
5'-hydroxy-lornoxicam and only negligible amounts of intact lornoxicam are excreted unchanged 
in the urine.  
Excretion 
            Excreted in the faeces (as metabolites) and urine (as unchanged drug). Approximately 2/3 
of the drug is eliminated via the liver and 1/3 via the kidneys in the active form. Mean 
elimination half life of 3-4 hours. 
 
PHARMACODYNAMICS 
LOX is a potent inhibitor of the COX enzymes, which are responsible for catalyzing the 
formation of prostaglandins and thromboxane from arachidonic acid. Unlike some NSAIDS, 
lornoxicam's inhibition of COX does not lead to an increase in leukotriene formation and the 
arachidonic acid is not moved to the 5-lipoxygenase cascade, resulting in the minimization of the 
risk of adverse effects. 
 
MECHANISM OF ACTION 
 LOX's anti-inflammatory and analgesic activity is related to its inhibitory action on 
prostaglandin and thromboxane synthesis through the inhibition of both COX-1 and COX-2. 
This leads to the reduction of inflammation, pain, fever and swelling, which are mediated by 
prostaglandins. 
 
INDICATION AND USAGE 
LOX is used for the treatment of various types of pain, especially resulting from 
inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations of 
the joints caused by certain types of rheumatic diseases. 
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DOSAGE 
Post Operative Pain management: 8-16 mg/day. Max: 24 mg/day.  
Osteoarthritis and Rheumatoid arthritis: 12mg/day in 2 -3 divided doses, up to 16mg/day. 
  
SIDE EFFECTS 
 LOX has more common side effects like GI disorders (nausea and diarrhea) 
and headache. Severe but seldom side effects include bleeding and bronchospasms. 
 
CONTRAINDICATIONS 
 Patients with peptic ulceration, severe renal impairment, pregnancy and lactation. 
 
INTERACTIONS 
 Enhanced effects of anticoagulants, Sulfonylurea, Methotrexate, Cyclosporin, Digoxin 
and decreased effects of diuretics and ACE inhibitors when administered along with LOX. 
 
ADVERSE REACTIONS 
Abdominal pain, diarrhoea, dizziness, dyspepsia, nausea, vomiting, headache, 
haematologic disorders. 
 
AVAILABLE MARKETED PRODUCTS 
Camri tabs            - Cadila 
Flexilor inj,tab             - Glenmark 
Fulactive inj, fulactive 4P, 8P tab  - Ranbaxy 
Lanagesic tab                       - Wockhardt 
Lofecam tab                                  - Sun Pharma 
Lorcheck P                                    - Indoco 
Lornasafe tab                                - Mankind 
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EXCIPIENT PROFILE 
MANNITOL70 
1. Nonproprietary Names  
  BP: Mannitol, JP: D-Mannitol, PhEur: Mannitol, USP: Mannitol. 
2.    Synonym   
   Cordycepic acid, Emprove, Manna sugar, D-mannite, Mannite, Mannitolum, 
Mannogem, Pearlitol. 
3.    Empirical Formula 
   C6H14O6 
4.    Molecular Weight 
   182.17 
5.    Chemical Name 
   D-Mannitol 
6.    Structural Formula 
 
7.    Functional Category  
  Diluent, plasticizer, sweetening agent, tablet and capsule diluents, therapeutic  and 
tonicity agent. 
8.    Description 
  Mannitol occurs as a white, odourless, crystalline powder or free flowing 
granules.  It has a sweet taste and imparts a cooling sensation in the mouth. Microscopically, 
it appears as orthorhombic needles when crystallized from alcohol. 
9. Solubility 
  Soluble in water, very slightly soluble in ethanol, practically insoluble in ether. 
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10.  Incompatibilities 
  Mannitol solutions (20% w/v or stronger) may be salted out by potassium chloride 
or sodium chloride. Mannitol is incompatible with xylitol infusion and may form complexes 
with some metals such as aluminum, copper and iron. 
11.  Applications  
  Used as an osmogen in osmotic pumps which aids in releasing the drug.    
Mannitol is widely used in Pharmaceutical formulations and food products. In pharmaceutical 
preparations it is primarily used as an excipient (10–90% w/w) in tablet formulations. It is 
commonly used as an excipient in the manufacture of chewable tablet formulations because of 
its negative heat of solution, sweetness and ‘mouth feel’. 
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1. Nonproprietary Names 
  Tris buffer.  
2.   Synonym   
             Tris (Hydroxymethyl) 
Tris(hydroxymethyl)methylamine, 
3.   Empirical Formula 
   C4H11NO3. 
4.   Molecular Weight 
   121.14 
5.  Chemical Name 
   2-Amino-2-Hydroxymethyl
6. Structural Formula 
7.  Functional Category  
  Buffer solution or
 8.  Description 
  White, Crystalline 
  9.Solubility 
  Easily soluble in cold water, hot water. Partially soluble in methanol, acetone.
10.  Incompatibilities 
  Incompatible with 
aldehydes. 
 
Excipient Profile
Medical College 
TROMETHAMINE70 
aminomethane, addex-tham, Tromethanmin
Tromethamine, Addex-Tham. 
-m 1,3-Propanediol. 
 
 alkalizer for the correction of metabolic acidosis
powder, Slight characteristic odour, faint sweet soapy taste.
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11. Application  
         It is used in the synthesis of surface-active agents and as an emulsifying agent for 
cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer and 
used as an alkalizer. 
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SODIUM LAURYL SULPHATE70 
1. Nonproprietary Names 
              BP: Sodium lauryl sulfate, JP: Sodium lauryl sulfate, PhEur: Natrii laurilsulfas 
USPNF: Sodium lauryl sulfate. 
2. Synonyms 
              Dodecyl sodium sulfate, Elfan 240, sodium dodecyl sulfate, sodium laurilsulfate, 
sodium monododecyl sulfate, sodium monolauryl sulfate. 
3. Empirical Formula 
              C12H25NaO4S 
4. Molecular Weight 
              288.38. 
5. Chemical Name 
           Sulfuric acid monododecyl ester sodium salt 
6. Structural Formula 
   
 
 
 
7. Functional Category  
        Anionic surfactant, detergent, emulsifying agent, skin penetrant, tablet and capsule 
lubricant, wetting agent. 
8. Description 
       Sodium lauryl sulfate consists of white or cream to pale yellow-coloured crystals, 
flakes, or powder having a smooth feel, a soapy, bitter taste and a faint odour of fatty 
substances. 
9. Solubility 
      Freely soluble in water, giving an opalescent solution, practically insoluble in 
chloroform and ether. 
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10. Incompatibilities 
           Sodium lauryl sulfate reacts with cationic surfactants causing loss of activity even in 
concentrations too low to cause precipitation. It is also incompatible with some alkaloidal 
salts and precipitates with lead and potassium salts. 
  
11.  Application 
          Used as a Solubilizer in concentrations greater than critical micelle concentration. 
anionic emulsifier, skin cleanser in topical applications, tablet lubricant and wetting agent in 
dentrifices. 
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LACTOSE70 
1. Nonproprietary Names 
              BP: Lactose, PhEur: Lactose Monohydrate, JP: Lactose Hydrate, USP-NF: Lactose 
Monohydrate. 
2. Synonyms 
            CapsuLac, GranuLac, Lactochem, Lactosum monohydricum, Monohydrate. 
3. Empirical Formula 
            C12H22O11 H2O 
4. Molecular Weight  
        360.31. 
5. Chemical Name 
            Lactose 
6. Functional Category  
         Dry powder inhaler carrier, lyophilization aid, tablet binder, tablet and capsule diluent, 
tablet and capsule filler. 
7. Description 
        Lactose occurs as white to off-white crystalline particles or powder. Lactose is 
odourless and slightly sweet-tasting. 
8. Solubility 
        Freely but slowly soluble in water, Practically insoluble in alcohol. 
9. Incompatibilities 
            A Maillard-type condensation reaction is likely to occur between lactose and 
compounds with a primary amine group to form brown or yellow-brown-coloured products. 
Lactose is also incompatible with amino acids, amphetamines and lisinopril. 
10.  Application 
              Lactose is widely used as a filler and diluent in tablets, capsules and dry-powder 
Inhalation. 
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TALC70 
1. Nonproprietary Names 
               BP: Purified Talc, JP: Talc, PhEur: Talc, USP: Talc. 
2. Synonyms 
   Magnesium hydrogen metasilicate, Magsil Osmanthus, Magsil Star. 
3. Empirical Formula 
               Mg6(Si2O5)4(OH)4. 
4. Chemical Name 
               Talc. 
 5. Functional Category  
   Anticaking agent, glidant, tablet and capsule diluent, tablet and capsule lubricant. 
  6. Description 
   Talc is a very fine, white to grayish-white, odourless, impalpable, unctuous, 
crystalline powder. 
   7. Solubility 
          Practically insoluble in dilute acids and alkalis, organic solvents and water. 
   8. Incompatibilities 
               Incompatible with quaternary ammonium compounds. 
   9. Application  
              Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluents. It is widely used as a dissolution retardant in the development of controlled-release 
products. Talc is additionally used to clarify liquids and is also used in cosmetics and food 
products, mainly for its lubricant properties. 
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COLLOIDAL SILICON DIOXIDE70 
1. Nonproprietary Names 
   BP: Colloidal Anhydrous Silica, JP: Light Anhydrous Silicic Acid, PhEur:          
Silica, Colloidal Anhydrous, USP-NF: Colloidal Silicon Dioxide. 
2.  Synonyms 
   Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, colloidal silica, fumed silica, fumed silicon 
dioxide. 
3.  Empirical Formula 
                  SiO2 
4.  Molecular Weight  
                           60.08 
5.  Chemical Name 
              Silica 
6.  Functional Category  
   Adsorbent, anti caking agent, emulsion stabilizer, glidant, suspending agent, tablet 
disintegrant, thermal stabilizer, viscosity-increasing agent. 
7.  Description  
             Colloidal silicon dioxide is a submicroscopic fumed silica with a particle size of 
about 15 nm. It is a light, loose, bluish-white-coloured, odourless, tasteless, amorphous 
powder. 
 8. Solubility 
              Practically insoluble in organic solvents, water  and acids. soluble in hot solutions 
of alkali hydroxide. 
9. Incompatibilities 
            Incompatible with diethylstilbestrol preparations. 
10. Applications  
            Colloidal silicon dioxide is widely used in pharmaceuticals,cosmetics and food 
products. Colloidal silicon dioxide is also used to stabilize emulsions and as a thixotropic 
thickening and suspending agent in gels and semisolid preparations 
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MAGNESIUM STEARATE70 
1. Nonproprietary Names 
        BP: Magnesium stearate, JP: Magnesium stearate, PhEur: Magnesii stearas.           
USP NF: Magnesium stearate. 
2. Synonyms 
           Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic acid. 
3. Chemical Name 
            Octadecanoic acid magnesium salt. 
4. Empirical Formula 
            C36H70MgO4 
5. Molecular Weight 
             591.34 
6. Functional Category 
            Tablet and capsule lubricant. 
7. Description 
            Magnesium stearate is a very fine, light white, precipitated or milled, having a faint 
odour of stearic acid and a characteristic taste. The powder is greasy to touch and readily 
adheres to the skin. 
8. Solubility 
             Practically insoluble in ethanol, ethanol (95%), ether and water, slightly soluble in 
warm benzene and warm ethanol (95%). 
9. Incompatibilities 
           Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin, some 
vitamins, and most alkaloidal salts. 
10. Applications                                                                                                                                                               
       It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25-5.0% w/w. It is also used in barrier creams. 
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CELLULOSE ACETATE70 
1. Nonproprietary Names 
   BP: Cellulose Acetate, PhEur: Cellulose Acetate, USP-NF: Cellulose Acetate 
2. Synonyms 
   Acetic acid, cellulose ester. acetyl cellulose, cellulose diacetate. 
3. Chemical Name  
   Cellulose acetate. 
 4. Empirical Formula 
   C6H7O2(OH)3 
5. Molecular Weight 
   38000 
6. Functional Category 
           Coating agent, extended release agent, tablet and capsule diluents. 
7. Description 
  Cellulose acetate occurs as a white to off-white powder, free-flowing pellets, or 
flakes. It is tasteless and odourless, or may have a slight odour of acetic acid. 
8. Solubility: 
  Practically insoluble in water, soluble in acetone, in formic acid and in a mixture 
of equal volumes of methanol and methylene chloride, practically insoluble in alcohol. 
9. Incompatibilities 
            Incompatible with strongly acidic or alkaline substances. Cellulose acetate is 
compatible with plasticizers like diethyl phthalate, triacetin and triethyl citrate. 
10. Applications  
            Cellulose acetate is used as a semipermeable coating on tablets, especially on 
osmotic pump type tablets and implants. Cellulose acetate and other cellulose esters have also 
been used to form drug-loaded microparticles with controlled-release characteristics. 
Cellulose acetate films are used in transdermal drug delivery systems and also as film 
coatings on tablets or granules for taste masking. 
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SORBITOL70 
1.  Nonproprietary Names 
  BP: Sorbitol, JP: D-Sorbitol, PhEur: Sorbitolum, USPNF: Sorbitol. 
2.  Synonyms 
  PharmSorbidex  E420, 1,2,3,4,5,6-hexanehexol, Liponic 70-NC, Liponic 76-NC. 
3.  Chemical Name  
  D-Glucitol 
4.  Empirical Formula  
  C6H14O6 
5.  Molecular Weight 
  182.17 
6.  Functional Category 
  Humectant, plasticizer, sweetening agent, tablet and capsule diluents. 
7.  Description 
  Sorbitol occurs as an odourless, white or almost colourless, crystalline, 
hygroscopic powder. 
8.  Solubility 
  Very soluble in water, slightly soluble in ethanol. 
9. Incompatibilities 
  Sorbitol will form water-soluble chelates with many divalent and trivalent metal 
ions in strongly acidic and alkaline conditions. 
10. Applications 
  Sorbitol is used as a diluent in tablet formulations prepared by either wet 
granulation or direct compression. It is particularly useful in chewable tablets owing to its 
pleasant, sweet taste and cooling sensation. In capsule formulations it is used as a plasticizer 
for gelatin. It has been used as a plasticizer in film formulations. In liquid preparations 
sorbitol is used as a vehicle in sugar-free formulations and as a stabilizer for drug, vitamin, 
and antacid suspensions. Sorbitol is additionally used in injectable and topical preparations 
and therapeutically as an osmotic laxative. 
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POVIDONE70 
1.  Nonproprietary Name 
        Povidone 
2.  Synonyms 
            E1201, Kollidon, Plasdone, Poly[1-(2-oxo-1-pyrrolidinyl)ethylene], Polyvidon. 
3.  Chemical Name 
                 1-Ethenyl-2-pyrrolidinone homopolymer. 
4.  Empirical Formula  
                (C6H9NO) n 
5. Molecular Weight 
                2500–3,000,000 
6.  Functional Category 
                Disintegrant, dissolution enhancer, suspending agent, tablet binder. 
7.  Description 
                Povidone occurs as a fine, white to creamy-white coloured, odourless or almost 
odourless, hygroscopic powder.  
8.  Solubility 
  Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol and water. 
Practically insoluble in ether, hydrocarbons and mineral oil. 
9.  Incompatibility 
     It forms molecular adducts in solution with sulfathiazole, sodium salicylate, 
salicylic acid, phenobarbital, tannin. 
   10. Applications 
                Povidone is used in a variety of Pharmaceutical formulations primarily used in 
solid-dosage forms. In tableting, povidone solutions are used as binders in wet-granulation 
processes. Povidone is used as a solubilizer in oral and parenteral formulations and has been 
shown to enhance dissolution of poorly soluble drugs from solid-dosage forms. It is also used 
as a suspending, stabilizing, or viscosity-increasing agent in a number of topical and oral 
suspensions and solutions. 
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POLYETHYLENE GLYCOL 40070 
1. Nonproprietary Names 
   BP: Macrogols, JP: Macrogol 400, PhEur: Macrogola, USPNF: Polyethylene 
glycol. 
2. Synonyms 
  Carbowax, Lipoxol, Lutrol E, PEG, Pluriol , Polyoxyethylene glycol. 
3. Chemical Name  
  Hydro-hydroxy poly(oxy-1,2-ethanediyl). 
4. Empirical Formula  
                HOCH2(CH2OCH2)mCH2OH where m represents the average number of 
oxyethylene groups. 
5.  Molecular Weight 
  380–420 
6. Functional category 
  Ointment base, plasticizer, solvent, suppository base, tablet and capsule lubricant. 
7. Description 
  Liquid grades (PEG 200–600) occur as clear, colourless or slightly yellow-
coloured, viscous liquids. They have a slight but characteristic odour and a bitter, slightly 
burning taste. 
8. Solubility 
Polyethylene glycol is soluble in water and miscible in all proportions. 
9. Incompatibility 
  PEG can exhibit some oxidizing activity owing to the presence of peroxide 
impurities and secondary products formed by autoxidation. 
10. Applications 
   It is widely used in a variety of pharmaceutical formulations including parenteral, 
topical, ophthalmic, oral and rectal preparations. Liquid polyethylene glycols are used as 
water-miscible solvents for the contents of soft gelatin capsules. Polyethylene glycols are 
useful as plasticizers in microencapsulated products to avoid rupture of the coating film. 
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ISOPROPYL ALCOHOL70 
1.  Nonproprietary Names 
  BP: Isopropyl alcohol, JP: Isopropanol, PhEur: Alcohol isopropylicus,           
USP: Isopropyl alcohol. 
2.  Synonyms 
  Dimethyl carbinol, IPA, Isopropanol, 2-propanol. 
3.  Chemical Name  
  Propan-2-ol 
4.  Empirical Formula   
  C3H8O 
5.  Molecular weight 
  60.1 
6.  Functional Category 
  Disinfectant, solvent. 
7.  Description 
  Isopropyl alcohol is a clear, colourless, mobile, volatile, flammable liquid with a    
characteristic, spirituous odour resembling that of a mixture of ethanol and acetone; it has a 
slightly bitter taste. 
8.  Solubility 
  Miscible with benzene, chloroform, ethanol (95%), ether, glycerin and water. 
Soluble in acetone, insoluble in salt solutions. 
9. Incompatibility 
  Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, 
which cause decomposition. Isopropyl alcohol may be salted out from aqueous mixtures by 
the addition of sodium chloride, sodium sulfate and other salts, or by the addition of sodium 
hydroxide. 
10. Application 
  Isopropyl alcohol (propan-2-ol) is used in cosmetics and Pharmaceutical 
formulations, primarily as a solvent in topical formulations. Isopropyl alcohol is also used as a 
solvent both for tablet film-coating and for tablet granulation. 
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METHANOL71 
1.  Synonyms 
  Methyl alcohol, wood alcohol, wood naphtha or wood spirits. 
2.  Chemical Name  
  Hydroxymethane. 
3.  Empirical Formula  
  CH4O 
4.  Molecular weight 
  32.04 
5.  Functional Category 
  Common laboratory solvent. 
6.  Description 
  Clear, colourless, volatile, hygroscopic liquid. 
7.  Solubility 
  Miscible with water and methylene chloride. 
8. Incompatibilities 
  Methanol is incompatible with Chloroform and a base  explosive reaction. 
9. Applications 
Methanol is used as a solvent and as an anti freeze in pipeline and windshield 
washer fluid.  
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WATER70 
1. Nonproprietary Names 
   BP: Purified water, JP: Purified water, PhEur: Aqua purificata, USP: Purified 
water. 
2. Synonyms 
  Aqua; Hydrogen oxide. 
3. Chemical Name  
  Water 
 4. Empirical Formula  
  H2O 
5. Molecular Weight 
  18.02 
6. Functional Category 
  Solvent 
7. Description 
  Water is a clear, colourless, odourless and tasteless liquid. 
8. Solubility 
  Miscible with most polar solvents. 
9. Incompatibilities 
  In Pharmaceutical formulations, water can react with drugs and other excipients 
that are susceptible to hydrolysis at ambient and elevated temperatures. Water can react 
violently with alkali metals and rapidly with alkaline metals and their oxides, such as calcium 
oxide and magnesium oxide. Water also reacts with anhydrous salts to form hydrates of 
various compositions and with certain organic materials and calcium carbide. 
10. Applications 
  Water is widely used as a raw material, ingredient and solvent in the processing, 
formulation and manufacture of pharmaceutical products, active pharmaceutical ingredients 
(API) and intermediates and analytical reagents. 
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DICHLOROMETHANE70 
1.  Nonproprietary Names 
   Methylene dichloride, Solmethine, Narkotil, Solaesthin, Di-clo, Freon 30, R-30, 
DCM, UN 1593, MDC. 
2.  Synonym 
   Methylene chloride 
3.  Empirical Formula 
      CH2Cl2 
4.  Molecular Weight 
       84.93 
5. Chemical Name 
      Dichloromethane 
6.  Functional Category 
     Solvent 
7.  Description  
     Colourless, volatile liquid with a moderately sweet aroma. 
8.  Solubility 
     It is not miscible with water, it is miscible with many organic solvents. 
9.  Incompatibilities 
   Incompatible with Diethylstilbestrol preparations. 
10.  Applications  
   It is used to dissolve a wide range of organic compounds makes it a useful solvent 
for many chemical processes. It is widely used as a paint stripper and a degreaser.  It is used as 
an aerosol spray propellant and as a blowing agent for polyurethane foams. 
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MATERIALS AND METHODS 
The list of drug and excipients, their manufacturer and use in the present study are shown in 
table 6.1 
Table 6.1: List of Materials Used 
S.No. Drug/Excipient Manufacturer Use in Formulation 
1 Lornoxicam Glenmark Active Ingredient 
2 Mannitol S.D.Fine Chemicals, Mumbai. Osmogen 
3 Tromethamine S.D.Fine Chemicals, Mumbai. Alkaliser 
4 Sodium lauryl sulphate S.D.Fine Chemicals, Mumbai. Solubilizer 
5 Lactose D.M.V International. Diluent 
6 Poly vinyl pyrrolidone S.D.Fine Chemicals, Mumbai. Binder 
7 Talc S.D.Fine Chemicals, Mumbai. Glidant 
8 Magnesium Stearate Mudha enterprises Lubricant 
9 Aerosil Cabor Sanmar Ltd Glidant 
10 Cellulose acetate S.D.Fine Chemicals, Mumbai. Semipermeable membrane 
11 PEG 400 Qualigens Fine Chemicals, 
Mumbai 
Plasticizer 
12 Sorbitol S.D.Fine Chemicals, Mumbai. Poore former 
13 Iron oxide yellow Colorcon Asia Limited Colouring agent 
14 Methanol Qualigens Fine Chemicals, 
Mumbai 
Solvent 
15 Dichloromethane Qualigens Fine Chemicals, 
Mumbai 
Solvent 
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The list of instruments/ equipments used in the present study and their manufacturer 
are shown in table 6.2. 
 
Table 6.2: List of Instruments / Equipments 
 
S.No. Instruments/ Equipments Manufacturer 
1  Electronic Weighing balance Shimadzu, Japan. 
2 Tray dryer Chitra, Ahmedabad. 
3 Hot air oven Industrial Heaters, Chennai. 
4 27 station rotary compression machine Cadmach, Ahmedabad. 
5 Coating Machine Cadmach, Ahmedabad. 
6 Vernier Caliper Mitutoyo, Japan. 
7 Monsanto Harness Tester Erweka, Mumbai. 
8 Friabilator Electrolab, India 
9 pH meter Synchrony India 
10 Sonicator Toshniwal, Ajmeer 
11 Dissolution Test Apparatus  Electrolab, India 
12 UV-Visible Spectrophotometer Shimadzu, Japan 
13 Fourier Transform Infra Red Spectrophotometer Nicolet 
15 Stability chamber Technico, India 
16 SEM Analyzer Hitachi, Japan. 
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PHYSICAL COMPATIBILITY STUDY 72 
The physical admixture of the drug and excipients so as to reflect those expected to be 
present in the final product were taken in 2 ml glass vials and sealed. These glass vials were 
kept at room temperature and at 40⁰ ± 2⁰C / 75% ± 5% RH for 1 month. At the end of 10 days, 
the samples were withdrawn and analyzed for colour change. 
 
FTIR STUDY- IDENTIFICATION AND COMPATIBILITY OF DRUG AND  
POLYMER 73 
Infrared Spectroscopy was conducted using FTIR spectrophotometer and the spectrum 
was recorded in the wavelength region of 4000 to 400 cm-1. The procedure consisted of 
dispersing the sample (drug alone, mixture of drug and excipients and the optimized 
formulation) in KBr and compressed into discs by applying a pressure of 5 Tons for 5minutes 
in a hydraulic press. The pellet was placed in the light path and the spectrum was recorded. 
 
STANDARD CURVE FOR LORNOXICAM51 
Standard curve in 0.1 N Hydrochloric Acid Buffer pH 1.2 
 50 mg of lornoxicam was weighed, transferred to 50 ml standard flask and dissolved in 
equal proportions of methanol(25ml) and 0.1N Hydrochloric Acid buffer pH 1.2 (25ml) to get 
a concentration of 1mg/ml. From the stock solution 10ml was taken and diluted to 100ml with 
0.1N Hydrochloric Acid buffer pH 1.2 to get a concentration of 100mcg/ml. The above 
solution was further diluted with to get a concentrations of 2, 4, 6,8,10 mcg/ml. The 
absorbance of the resulting solution was measured at 376nm using UV-Visible 
Spectrophotometer taking 0.1N Hydrochloric acid acid buffer pH1.2 as blank. 
 
Standard curve in Acetate Buffer pH 4.5 
 50 mg of lornoxicam was weighed, transferred to 50ml standard flask and dissolved in 
equal proportions of methanol(25ml) and Acetate buffer pH 4.5 (25ml) to get a concentration 
of 1mg/ml. From the stock solution 10ml was taken and diluted to 100ml with Acetate buffer 
pH 4.5 to get a concentration of 100mcg/ml. The above solution was further diluted to get a 
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concentrations of 2, 4, 6,8,10 mcg/ml. The absorbance of the resulting solution was measured 
at 376nm using UV-Visible Spectrophotometer taking Acetate buffer pH 4.5 as blank. 
 
Standard curve in Phosphate Buffer, pH 6.8 
 50 mg of lornoxicam was weighed, transferred to 50ml standard flask and dissolved in 
equal proportions of methanol (25ml) and Phosphate buffer pH 6.8 (25ml)  to get a 
concentration of 1mg/ml. From the stock solution 10ml was taken and diluted to 100ml with 
Phosphate buffer pH 6.8 to get a concentration of 100mcg/ml. The above solution was further 
diluted to get a concentrations of 2, 4, 6,8,10 mcg/ml. The absorbance of the resulting solution 
was measured at 376nm using UV-Visible Spectrophotometer taking Phosphate buffer pH 6.8 
as blank. 
 
PRECOMPRESSION STUDIES OF THE DRUG AND BLENDS 
BULK DENSITY (ρb) 74 
 Bulk Density (g/ml) is a term obtained by dividing weight of powder by bulk volume of 
powder. 25 g of the drug, powder blend and granules from each formula was introduced into a 
100 ml measuring cylinder. The cylinder was allowed to fall under its own weight onto a hard 
surface from the height of 2.5 cm at 2 second intervals for three times. Bulk Density is 
calculated using the following formula  
Bulk density, ρb = W / Vb 
Where,  W = Weight of the powder in g  
  Vb = Bulk volume of the powder in ml 
 
TAPPED DENSITY (ρt) 74  
Tapped Density (g/ml) is a term obtained by dividing weight of powder by tapped 
volume of powder. 25 g of the drug, powder blend and granules from each formula was 
introduced into a 100 ml measuring cylinder. The cylinder was allowed to fall under its own 
weight onto a hard surface from the height of 2.5 cm at 2 second intervals for 500 times. 
Tapped Density is calculated using the following formula  
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Tapped Density, ρt = W / Vt 
Where,  W = Weight of the powder in g  
  Vt = Tapped volume of the powder in ml 
 
COMPRESSIBILITY INDEX OR CARR’S INDEX (CI) 74  
It is an indirect measure of Bulk Density, size and shape, surface area, moisture content 
and cohesiveness. It is expressed in percentage and can be calculated by following equation  
Carr’s Index, CI = (ρt - ρb) / ρt x 100 
Where,  ρb = Bulk Density in g/ml 
  ρt = Tapped Density in g/ml  
 
 HAUSNER’S RATIO (HR) 74 
It is measured by the ratio of tapped density to bulk density. Ideal range should be 
between 1.2 and 1.5. It is calculated by the following formula 
Hausner’s Ratio, HR = ρt / ρb 
Where,  ρb = Bulk Density in g/ml 
  ρt = Tapped Density in g/ml  
 
ANGLE OF REPOSE (θ) 75 
The angle of repose of the drug, powder blend and granules from each formula was 
determined by the fixed funnel method which employs a funnel that is secured with its tip at 2 
cm above graph paper that is placed on a flat horizontal surface. From the radius of base of 
conical pile, angle of repose can be determined using following equation,  
Angle of Repose, θ = tan-1 (h/r) 
Where, h = height of the pile of powder in cm.  
  r = radius of the pile of powder base in cm. 
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Table 6.3:  Angle of Repose, Carr’s Index and Hausner’s Ratio 76 
 
Flow Property 
Angle of repose 
(θ in degrees) 
Carr’s Index 
(CI in %) 
Hausner’s 
Ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very poor >66 >38 >1.60 
 
FORMULATION DEVELOPMENT 
Preparation of lornoxicam granules and compaction into tablets: 
 The lornoxicam tablets were prepared with varying ratios of the osmogen (Mannitol). 
Drug and all the ingredients except lubricants were weighed and passed through sieve no. 20. 
The powders were mixed together. To the resultant powder mixture, PVP dissolved in 
isopropyl alcohol was added to form a coherent mass. Then the coherent mass was passed 
through 16 mesh screen to form granules. The wet granules were dried at 500C for 15 
minutes. The dried granules were passed through sieve no. 20 to break the lumps and to get 
uniform particle size of granules. The lubricant was passed through sieve no. 40 and mixed 
with the dried granules.  
 The lubricated granules were compressed into tablets using 11/32 inches (8.0mm) 
standard concave punches on a 27 station rotary tablet punching machine. The composition of 
core tablet is listed in Table 6.4.  
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Table 6.4: COMPOSITION OF CORE TABLETS 
S.No Ingredients F01(mg) F02(mg) F03(mg) F04(mg) 
1 Lornoxicam 8 8 8 8 
2 SLS 12 12 12 12 
3 Tromethamine 25 25 25 25 
4 Mannitol 0 50 100 150 
5 Lactose 187 137 87 37 
6 Povidone K30 12 12 12 12 
7 Isopropyl alcohol q.s q.s q.s q.s 
8 Magnesium Stearate 2.5 2.5 2.5 2.5 
9 Talc 2.5 2.5 2.5 2.5 
10 Aerosil 1 1 1 1 
Total Weight 250 mg 
 
COATING OF TABLETS 
Controlled porosity Osmotic coating 
 Three coating solutions of cellulose acetate in a mixture of methanol and 
dichloromethane containing different levels (0%, 10% and 20% w/v) of pore-forming agent 
(sorbitol) were prepared for semi permeable membrane coating. The composition of coating 
solutions is given in Table 6.5. PEG 400 acted as a hydrophilic plasticizer and was added to 
enhance the physical and mechanical property of cellulose acetate membrane.  
The coating conditions were as follows:                      
 Stainless steel pan with 200mm diameter 
 Rotation rate of the pan - 40 rpm 
 Nozzle diameter of spray gun - 1 mm 
 Spray rate - 3 ml/min 
 Drying temperature - 400C   
After coating, the tablets were dried at 500C to remove residual solvent.  
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Table 6.5: COMPOSITION OF COATING SOLUTION 
S.No Ingredients C1 C2 C3 
1 Cellulose acetate 60g 60g 60g 
2 Sorbitol - 6g 12g 
3 PEG 400 6g 6g 6g 
4 Water 58ml 58ml 58ml 
5 Dichloromethane 870ml 870ml 870ml 
6 Methanol 580ml 580ml 580ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials & Methods 6 
 
Department of Pharmaceutics, Madras Medical College Page 75 
 
Schematic representation of formulation development of controlled porosity osmotic 
tablets of Lornoxicam 
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EVALUATION OF TABLETS 
 
Description 
 Ten tablets were placed in a petri dish. The tablets were observed from both sides for 
colour, shape and visual appearance of tablets. 
 
Uniformity of Weight 77 
 Twenty tablets were selected at random from each batch. The individual tablets were 
weighed. The average weight is determined. The individual weight of tablets was compared 
with the average weight. 
Table 6.6: Uniformity of weight 
S.No Average Weight of  tablet %Deviation 
1 80 mg or less 10 
2 80-250 mg 7.5 
3 More than 250 mg 5 
 
Diameter and Thickness 78  
 Five tablets from each formulation were selected. The diameter and thickness of the 
tablets was measured using Vernier calipers. 
 
Hardness 78  
 The resistance of tablets to chipping or breakage during storage, transportations and 
handling before usage depends on its hardness. Five tablets were selected randomly and the 
hardness was measured by Monsanto hardness tester in terms of Kg/cm2.  
 
Friability 77, 78  
 Friability of tablets was measured using Roche friabilator. Twenty tablets were weighed 
and then placed in the chamber. The friabilator was set for 100 revolutions and the tablets 
were subjected to the combined effects of shock and abrasion because the plastic chamber 
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drops the tablets at a distance of six inches during every revolution. The tablets were dusted to 
remove the powder and reweighed. The friability is given by the formula: 
F = (1- W / WO) x 100 
Where  
WO is the weight of tablets before test. 
W is the weight of tablet after test. 
 
Drug Content 41 
 Ten tablets were weighed and ground. The weight equivalent to 8mg of drug was taken 
and transferred to a 100ml standard flask. 25ml of methanol and 25ml of 6.8 pH phosphate 
buffer was added and sonicated for 10minutes and the volume was made up to 100ml with 
equal volume of methanol and 6.8 pH phosphate buffer. The above solution was filtered and 
10ml of filtrate was taken and diluted to 100ml with 6.8 pH phosphate buffer. The absorbance 
of resulting solution was measured at 376nm and the content of LOX was calculated. 
 
Uniformity of content 77  
 Ten tablets were randomly selected and tested for their drug content.  
 
 In vitro release study of the tablets 79  
Two step-dissolution conditions was used in USP Type II (paddle) dissolution apparatus 
to simulate the physiological conditions of GIT - 2 hours in 900 ml of simulated gastric fluid 
(SGF pH 1.2) and 22 hours in 900 ml of simulated intestinal fluid (SIF, pH 6.8). The stirring 
rate was 100 rpm and the temperature was maintained at 37 ± 0.5°C. Aliquots of dissolution 
medium were withdrawn at predetermined time intervals and the same volume of medium 
was replenished to maintain the consistent volume. The absorbance of the solutions was 
measured at 376nm and the release was calculated. 
 
 
 
 
Materials & Methods 6 
 
Department of Pharmaceutics, Madras Medical College Page 78 
 
EVALUATION OF OPTIMIZED FORMULATION  
Effect of Change in Agitation Speed on drug release 80  
In order to study the effect of agitational intensity on the optimized formulation, release 
studies were also performed in dissolution apparatus at various rotational speeds of 50, 100 
and 150 rpm using two step-dissolution conditions 2 hours in 900 ml of SGF pH 1.2 and 22 
hours in 900 ml of SIF pH 6.8 in USP Type II (paddle) dissolution apparatus. The temperature 
was maintained at 37±0.5°C. The release was studied at predetermined time intervals. 
 
Effect of pH on drug release 81 
 In order to study the effect of pH of release medium in the drug release of optimized 
formulation, the in vitro release study was carried out in buffers of different pH, viz pH 1.2 
buffer, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer in USP type II dissolution 
apparatus. The temperature was maintained at 37⁰ ± 0.5⁰C. The release was studied at 
predetermined time intervals. 
 
Effect of Osmotic Pressure 27 
 To confirm the major mechanism of drug release, release studies of the optimized 
formulation was conducted in release media of different osmotic pressure. To increase the 
osmotic pressure of the release media (pre-equilibrated to 37⁰ ± 1⁰C), mannitol (osmotically 
effective solute) was added to produce 1.5 atm, 3 atm and 4.5 atm respectively.  The release 
was studied at predetermined time intervals. 
 
MEMBRANE MORPHOLOGY OF POROUS OSMOTIC TABLET  
 
Scanning Electron Microscopy27 
 Coating membranes of formulation obtained before and after complete dissolution of core 
contents were examined for their porous morphology by scanning electron microscope. 
Membranes were dried at 45º C for 12 hours and stored between sheets of wax paper in a 
dessicator until examination. The membrane was coated under an argon atmosphere with 
gold-palladium and observed with a scanning electron microscope.   
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RELEASE KINETICS OF THE OPTIMIZED FORMULATION 82-84   
  The in vitro release data for the optimized batch was fitted to various release 
kinetic models. The best fit was found out to describe the kinetics of drug release. 
Zero order release model  
 Zero order models describe the systems where the drug release rate is independent of its 
concentration.  
C = ko t 
Where, C -Cumulative percentage drug released  
ko -Zero-order constant  
t   -Time (Hours) 
A plot of time on x-axis and cumulative percentage drug released on y-axis gives a straight 
line with slope (ko) if it follows zero order kinetics.  
 
First order release model  
 First order model describe the systems where the release rate is dependent on the 
concentration.  
Log C = log Co – k t / 2.303 
Where C - Cumulative percentage drug remaining  
           Co - Initial concentration of drug  
      k - First order constant  
 A plot of time on x-axis and log cumulative percentage drug remaining on y-axis gives a 
straight line with slope (k / 2.303) if it follows first order kinetics. 
 
Higuchi release model  
The Higuchi model describes the release from where the solid drug is dispersed in an 
insoluble matrix and the rate of release is related to the rate of drug diffusion.  
Q = k t1/2 
Where Q – Cumulative percentage drug released  
    k – Constant reflecting the design variables of the system  
Materials & Methods 6 
 
Department of Pharmaceutics, Madras Medical College Page 80 
 
           t – Time  
A plot of square root of time on x-axis and cumulative percentage drug released on y-axis 
gives a straight line if it follows Higuchi kinetics.  
 
Hixson-Crowell release model  
       The Hixson-Crowell cube root model describes the release from systems where there is a 
change in surface area and diameter of the tablets or particles.  
Qo1/3 – Qt1/3 = K HC t 
   Where Qt - Cumulative percentage drug released in time t  
           Qo - initial amount of the drug  
   K HC - the rate constant for Hixson-Crowell rate equation  
A plot of time on x-axis and cube root of cumulative percentage of drug remaining on y-axis 
gives a straight line if it follows Hixson-Crowell kinetics. 
 
Korsmeyer and Peppas Model 
Korsmeyer and Peppas model derive a simple relationship which describes the drug 
release from a polymeric system equation. 
Mt / M∞ = K t n 
Where    Mt / M∞ – fraction of drug released at time t  
               k - Release rate constant  
               n - Release exponent 
A plot of log time on x-axis and log cumulative percentage of drug released on y-axis gives a 
straight line if it follows Korsmeyer and Peppas kinetics. 
 
STABILITY STUDIES85 
Optimized formulation tablets were packed in blister and stored in stability chambers 
maintained at 40°C±2oC and 75%±5% RH for three months. After every month tablet samples 
were analyzed for physical appearance, drug content and in vitro release.  
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PHYSICAL COMPATIBILITY STUDY 
 To obtain a stable and efficacious dosage form, the excipients must be carefully selected 
so that the incompatibility problems do not arise. The result is shown in table 7.1. 
Table 7.1: Physical compatibility study of drug and excipients 
S.
No 
Drug & 
Excipient 
Description and Conditions 
Initial Room Temperature 400 ± 20C / 75 ± 5% RH 
10days 20days 30days 10days 20days 30days 
1 LOX Yellow coloured 
powder 
NC NC NC NC NC NC 
2 TR White coloured 
salt 
NC NC NC NC NC NC 
3 SLS White coloured 
powder 
NC NC NC NC NC NC 
4 ML White coloured 
powder 
NC NC NC NC NC NC 
5 LA White coloured 
powder 
NC NC NC NC NC NC 
6 MS White coloured 
powder 
NC NC NC NC NC NC 
7 TA White coloured 
powder 
NC NC NC NC NC NC 
8 AE White coloured 
powder 
NC NC NC NC NC NC 
9 CA Creamy white 
powder 
NC NC NC NC NC NC 
10 LOX+TR Yellow coloured 
powder 
NC NC NC NC NC NC 
11 LOX+SLS Yellow coloured 
powder 
NC NC NC NC NC NC 
12 LOX+ML Yellow coloured 
powder 
NC NC NC NC NC NC 
13 LOX+LA Yellow coloured 
powder 
NC NC NC NC NC NC 
14 LOX+MS Yellow coloured 
powder 
NC NC NC NC NC NC 
15 LOX+TA Yellow coloured 
powder 
NC NC NC NC NC NC 
16 LOX+AE Yellow coloured 
powder 
NC NC NC NC NC NC 
17 LOX+CA Yellow coloured 
powder 
NC NC NC NC NC NC 
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  The physical compatibility 
the drug and the excipients were physically compatible with each other.
FTIR STUDY – IDENTIFICATION AND C
EXCIPIENTS 
 The identification of drug and the compatibility between the 
excipients was carried out using FTIR. The FT
mixtures and final formulation
Fig. 7.1: FTIR Spectrum of Lornoxicam
                             Table 7.2: IR Interpretation of Lornoxicam
Wave Numbers (cm
            1646.51
Results and Discussion
 
study was performed visually. The results show that 
 
OMPATIBILITY OF DRUG AND 
drug and the different 
IR spectrum of the pure drug, 
 were shown in figures 7.1 to 7.6 and tables 7.2 to 
 
 
-1) Interpretation 
3066.61 Aromatic C-H Stretching
1425.35 C=C Stretching 
1501.35 C=N Stretching 
3100.96 N-H Stretching 
3542.28 O-H Stretching 
 C=O Stretching 
1382.07 SO2 Stretching 
870 S-N Stretching 
765.75 C-S Stretching 
 7 
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drug – excipients 
7.7. 
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Fig. 7.2: FTIR Spectrum of Lornoxicam and Mannitol 
 
Table 7.3: IR Interpretation of Lornoxicam and Mannitol 
Wave Numbers (cm-1) Interpretation 
3066.00 Aromatic C-H Stretching 
1418.76 C=C Stretching 
1540.70 C=N Stretching 
3100.00 N-H Stretching 
3542.00 O-H Stretching 
1591.41 C=O Stretching 
1382.00 SO2 Stretching 
881.27 S-N Stretching 
789.82 C-S Stretching 
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Fig. 7.3: FTIR Spectrum of Lornoxicam and Tromethamine
Table 7.4: IR Interpretation of Lornoxicam and Tromethamine
Wave Numbers (cm
Results and Discussion
 
 
-1) Interpretation 
3067.65 Aromatic C-H Stretching
1425.44 C=C Stretching 
1501.00 C=N Stretching 
3067.65 N-H Stretching 
3649.32 O-H Stretching 
1646.72 C=O Stretching 
1382.62 SO2 Stretching 
870.03 S-N Stretching 
765.87 C-S Stretching 
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Fig. 7.4: FTIR Spectrum of Lornoxicam and SLS
Table 7.5: IR Interpretation of Lornoxicam and SLS
Wave Numbers (cm
 
Results and Discussion
 
 
-1) Interpretation 
3067.32 Aromatic C-H Stretching
1424.50 C=C Stretching 
1539.72 C=N Stretching 
3100.00 N-H Stretching 
3560.05 O-H Stretching 
1646.00 C=O Stretching 
1382.85 
            SO2 Stretching
869.95 S-N Stretching 
765.51 C-S Stretching 
 7 
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Fig. 7.5: FTIR 
Table 7.6: IR Interpretation of Lornoxicam and Lactose
Wave Numbers (cm
 
 
Results and Discussion
 
Spectrum of Lornoxicam and Lactose
 
-1) Interpretation 
3067.32 Aromatic C-H Stretching
1427.00 C=C Stretching 
1543.00 C=N Stretching 
3093.00 N-H Stretching 
3526.00 O-H Stretching 
1643.00 C=O Stretching 
1382.85 SO2 Stretching 
869.95 S-N Stretching 
765.51 C-S Stretching 
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             Fig. 7.6: FTIR Spectrum of Lornoxicam Tablet
Table 7.7: IR Interpretation of Lornoxicam Tablet
Wave Numbers (cm
  
 From the FTIR spectra, 
with different excipients showed the presence of Lornoxicam characterist
wave number. This indicated
excipients. 
Results and Discussion
 
 
 
-1) Interpretation 
2932.14 Aromatic C-H Stretching
1429.36 C=C Stretching 
1500 C=N Stretching 
2932.14 N-H Stretching 
3420.64 O-H Stretching 
1648.40 C=O Stretching 
875.74 SO2 Stretching 
1335.83 S-N Stretching 
776.53 C-S Stretching 
it is clearly evident that the physical mixtures of Lornoxicam 
ics bands at their same 
 the absence of chemical interaction betw
 7 
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STANDARD CURVE OF LORNOXICAM 
 The UV Spectrophotometric method was used to analyze LOX. The absorbance of the 
drug in various buffers: 0.1 N HCl buffer pH 1.2, acetate buffer pH 4.5 and phosphate buffer 
pH 6.8 was measured at a wavelength of 376 nm. The results are given in table 7.8 and 
Fig.7.7 to 7.9. 
Table 7.8: Standard Curve of Lornoxicam 
  
 
 
 
 
 
 
 
 
 
Fig. 7.7: Standard Curve of Lornoxicam in Acid buffer pH 1.2 
 
y = 0.0426x + 0.0089
R² = 0.9983
0
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n
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Concentration mcg/ml
S. No. Concentration 
(mcg/ml) 
Absorbance at 376 nm 
 
pH 1.2 pH 4.5 
 
pH 6.8 
1 2 0.0971 0.0874 
 
0.0786 
2 4 0.1861 0.1705 
 
0.1477 
3 6 0.2698 0.2536 
 
0.2214 
4 8 0.3490 0.3366 
 
0.2950 
5 10 0.4280 0.4095 
 
0.3680 
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Fig. 7.8: Standard Curve of Lornoxicam in Acetate buffer pH 4.5 
 
 
Fig. 7.9: Standard Curve of Lornoxicam in Phosphate buffer pH 6.8  
The standard curve of lornoxicam in buffers pH 1.2, 4.5 and 6.8 are linear, starting from the 
origin. The curve obeys Beer Lambert law.51 
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PRECOMPRESSION STUDIES OF THE DRUG, BLENDS AND GRANULES 
 The result of precompression parameters for the drug and the formulated blends is given 
in table 7.9. 
Table 7.9: Precompression Study of Drug and Formulated Blends 
Drug & 
Formulation 
 
 
Bulk 
Density* 
(g/ml) 
Tapped 
Density* 
(g/ml) 
Compressibility 
Index*(%) 
Hausner’s 
Ratio* 
Angle of 
Repose*(θ) 
Drug 
 
0.711±0.002 1.103±0.002 35.53±0.16 1.55±0.06 30.15±0.23 
 
F01 
 
0.663±0.007 0.768±0.008 13.67±0.10 1.15±0.08 31.32±0.23 
 
F02 
 
0.674±0.004 0.783±0.012 13.92±0.12 1.16±0.09 28.44±0.29 
 
F03 
 
0.622±0.005 0.730±0.009 14.79±0.14 1.17±0.12 35.44±0.28 
 
F04 
 
0.678±0.012 0.797±0.014 
 
14.93±0.11 1.17±0.05 28.44±0.26 
*Mean ± SD (n=5) 
The Angle of Repose of the blend ranged from 28.440 to 35.440. The Hausner’s ratio of 
the formulated blends ranged from 1.15 to 1.17. The formulation blends showed poor – passable 
flow property.76 Hence the wet granulation technique was used. 
 
 
PRECOMPRESSION STUDIES OF DRUG AND GRANULES: 
 The result of pre compression studies of various formulations is given in table 7.10. 
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Table 7.10: Precompression Study of Drug and Granules 
 
Drug & 
Formulation 
 
 
Bulk 
Density* 
(g/ml) 
Tapped 
Density* 
(g/ml) 
Compressibility 
Index*(%) 
Hausner’s 
Ratio* 
Angle of 
Repose*(θ) 
F01 
 
0.510±0.004 0.585±0.007 12.82±0.21 1.14±0.03 19.44±0.16 
F02 
 
0.489±0.002 0.560±0.002 12.67±0.24 1.14±0.07 17.28±0.64 
F03 
 
0.479±0.003 0.534±0.006 10.29±0.28 1.11±0.05 19.43±0.17 
F04 
 
0.489±0.005 0.560±0.008 12.67±0.34 1.14±0.09 17.35±0.28 
*Mean ± SD (n=5) 
The Angle of repose of the blend ranged from 17.280 to 19.440 .The Hausner’s ratio of 
the formulated blends ranged from 1.11 to 1.14. The flow property of granules is excellent.76 
EVALUATION OF LORNOXICAM CORE TABLETS 
Uniformity of weight  
 Uniformity of weight of lornoxicam core tablets is given table 7.11. 
Table 7.11: Uniformity of weight of Lornoxicam core tablets 
Formulation Average weight of tablet*(g) 
F01 0.249±0.002 
 F02 0.249±0.001 
F03 0.252±0.003 
F04 0.249±0.001 
*Mean ± SD (n=5) 
The core tablets were uniform in weight.77  
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Thickness  
The thickness of core tablets is shown in table 7.12.  
Table 7.12: Thickness of Lornoxicam Core Tablets 
 
*Mean ± SD (n=5) 
The thickness of core tablets is found to be 3.27mm and 3.28 mm. The tablets have 
uniform thickness.  
Diameter  
 The diameter of core tablets is depicted in table 7.13. 
   Table 7.13: Diameter of Lornoxicam Core Tablets 
Formulation 
 
Diameter*(mm) 
F01 
 
8.76±0.0 
F02 
 
8.76±0.0 
F03 
 
8.77±0.0 
F04 
 
8.76±0.0 
*Mean ± SD (n=5) 
 The diameter of all the formulations was found to be 8.76mm and 8.77 mm. The tablets 
have uniform diameter. 
Formulation 
 
Thickness*(mm) 
F01 
 
3.27±0.0 
F02 
 
3.27±0.0 
F03 
 
3.28±0.0 
F04 
 
3.27±0.0 
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Hardness  
 The hardness of core tablets is shown in table 7.14. 
Table 7.14: Hardness of Lornoxicam core tablets 
Formulation 
 
Hardness* (kg/cm2) 
F01 
 
3.0±0.0 
F02 
 
3.1±0.0 
F03 
 
3.0±0.0 
F04 
 
3.0±0.0 
*Mean ± SD (n=5) 
 The hardness of lornoxicam core tablets was found to be between 3 kg/cm2 and              
3.1 kg/cm2. Hence the tablets have enough hardness to withstand stress during transport and 
handling.29 
Friability 
 The percentage friability of various formulations is depicted below in table 7.15. 
Table 7.15: Friability of Lornoxicam core tablets 
Formulation 
 
%Friability* 
F01 
 
0.16±0.023 
F02 
 
0.10±0.012 
F03 
 
0.12±0.025 
F04 
 
0.12±0.019 
 *Mean ± SD (n=5) 
The percentage friability of various formulations ranged from 0.10% to 0.16%. Hence the 
percentage friability complies with the official standard.77 
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EVALUATION OF LORNOXICAM COATED TABLETS 
Uniformity of weight  
 Uniformity of weight of all the formulations is given in table 7.16.  
Table 7.16: Uniformity of weight of Lornoxicam coated tablets 
Formulations Average weight of tablet*(g) 
F01C1 
 
0.278±0.003 
F01C2 
 
0.277±0.004 
F01C3 
 
0.277±0.002 
F02C1 
 
0.278±0.002 
F02C2 
 
0.277±0.003 
F02C3 
 
0.277±0.003 
F03C1 
 
0.277±0.002 
F03C2 
 
0.277±0.003 
F03C3 
 
0.276±0.002 
F04C1 
 
  0.275±0.002 
F04C2 
 
0.276±0.002 
F04C3 
 
0.277±0.003 
*Mean ± SD (n=5) 
The coated tablets were uniform in weight77 and the weight ranged between 0.275g and 
0.278 g. 
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Thickness  
 The thickness of all the coated formulations is given in table 7.17. 
Table 7.17: Thickness of Lornoxicam coated tablets 
Formulations Thickness*(mm) 
F01C1 3.542±0.014 
F01C2 3.538±0.028 
F01C3 3.568±0.019 
F02C1 3.560±0.025 
F02C2 3.546±0.016 
F02C3 3.574±0.008 
F03C1 3.542±0.034 
F03C2 3.580±0.015 
F03C3 3.568±0.013 
F04C1 3.566±0.005 
F04C2 3.570±0.033 
F04C3 3.566±0.005 
*Mean ± SD (n=5) 
 The thickness of coated tablet was between 3.538mm and  3.580 mm. The table have 
uniform thickness. 
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Diameter  
 The diameter of all the formulations is given in table 7.18. 
Table 7.18: Diameter of Lornoxicam coated tablets 
Formulations Diameter*(mm) 
F01C1 8.966±0.020 
F01C2 8.952±0.031 
F01C3 8.956±0.020 
F02C1 8.946±0.048 
F02C2 8.912±0.042 
F02C3 8.950±0.010 
F03C1 8.954±0.023 
F03C2 8.952±0.032 
F03C3 8.960±0.010 
F04C1 8.934±0.040 
F04C2 8.966±0.015 
F04C3 8.960±0.007 
*Mean ± SD (n=5) 
The diameter of coated tablet was found to be 8.912mm to 8.966 mm. The tablets have 
uniform diameter. 
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Hardness  
 The hardness of all the coated formulations is given in table 7.19 
 
Table 7.19: Hardness of Lornoxicam Coated Tablets 
Formulation 
 
Hardness* (kg/cm2) 
F01C1 5.7±0.273 
F01C2 5.7±0.447 
F01C3 5.6±0.418 
F02C1 5.7±0.273 
F02C2 5.5±0.353 
F02C3 5.6±0.418 
F03C1 5.5±0.353 
F03C2 5.2±0.570 
F03C3 5.9±0.273 
 F04C1 5.3±0.447 
F04C2 5.8±0.570 
F04C3 5.5±0.500 
*Mean ± SD (n=5) 
  The hardness of coated tablet ranged between 5.2 kg/cm2 and 5.8 kg/cm2. Hence 
the tablets have enough hardness to withstand stress during transport and handling.29 
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Friability 
 The friability of all the formulations is given in table 7.20. 
Table 7.20: Friability of Lornoxicam Coated Tablets 
Formulations Friability (%) 
F01C1 0.10±0.023 
F01C2 0.16±0.021 
F01C3 0.15±0.019 
F02C1 0.15±0.022 
F02C2 0.14±0.026 
F02C3 0.13±0.021 
F03C1 0.12±0.028 
F03C2 0.22±0.024 
F03C3 0.18±0.021 
 F04C1 0.62±0.022 
F04C2 0.71±0.027 
F04C3 0.70±0.023 
*Mean ± SD (n=5) 
  The friability of osmotic tablet ranged between 0.10% and 0.71 %. Hence the 
tablets have enough hardness to withstand stress during transport and handling.77 
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Drug Content 
 The content of active ingredients of various formulations was analyzed using UV 
spectrophotometer at 376 nm. The results of drug content are depicted in table 7.21. 
Table 7.21:   Drug content 
Formulations 
 
Drug Content* (%w/w) 
 
F01C1 100.84±1.403 
F01C2 95.61±0.894 
F01C3 97.33±0.976 
F02C1 100.91±0.955 
F02C2 99.08±1.110 
F02C3 97.29±0.998 
F03C1 95.26±0.987 
F03C2 99.46±1.098 
F03C3 97.15±1.143 
F04C1 95.98±0.987 
F04C2 98.33±1.056 
F04C3 99.05±1.123 
*Mean ± SD (n=5) 
 The percentage of drug content of all the formulations ranged from 95.61% w/w to 
100.91%w/w. All the formulations comply with the official standards. 
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Uniformity of content 
 The content of active ingredients of various formulations was analyzed using UV 
spectrophotometer at 376 nm. The results of drug content are depicted in table 7.22. 
Table 7.22:   Uniformity of content 
Formulation 
 
Drug Content* (%w/w) 
 
F01C1 99.04±0.989 
 
F01C2 97.23±0.709 
 
F01C3 100.23±0.231 
 
F02C1 99.87±0.897 
 
F02C2 98.99±1.110 
 
F02C3 95.90±0.289 
 
F03C1 
 
97.12±0.678 
F03C2 
 
99.98±0.092 
F03C3 
 
98.95±1.076 
F04C1 
 
98.98±0.678 
F04C2 
 
97.34±1.897 
F04C3 
 
100.23±1.021 
*Mean ± SD (n=10) 
 The drug content from all the formulations ranged from 95.90%w/w to 100.23%w/w. All 
the formulations comply with the test for uniformity of drug content77.  
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In vitro release study of the tablets: 
 The in vitro release of various formulations is shown in table 7.23 and figure 7.10. 
Table 7.23: In vitro release of the tablets 
Dissolution  
Medium 
Time 
in 
Hours 
Cumulative percentage drug release* 
F01C1 F02C1 F03C1 F04C1 F01C2 F02C2 F03C2 F04C2 F01C3 F02C3 F03C3 F04C3 
Acid Buffer 
pH 1.2 
0 0 0 0 0 0 0 0 0 0 0 0 0 
1 0.17 
±0.04 
0.50 
±0.40 
3.50 
±0.4 
3.76 
±0.48 
0.20 
±0.02 
2.76 
±0.02 
5.90 
±0.08 
9.00 
±0.05 
0.23 
±0.03 
3.29 
±0.56 
10.70 
±0.16 
12.09 
±0.91 
2 2.78 
±0.32 
6.14 
±0.56 
7.15 
±0.56 
7.49 
±0.69 
2.78 
±0.21 
6.14 
±0.36 
8.46 
±0.03 
11.50 
±0.49 
3.01 
±0.18 
8.65 
±0.28 
15.02 
±0.23 
18.68 
±0.56 
Phosphate 
Buffer  
pH 6.8 
3 9.02 
±0.55 
15.20 
±0.96 
18.38 
±0.58 
19.98 
±0.21 
11.96 
±1.04 
15.32 
±0.16 
17.52 
±0.08 
21.63 
±0.26 
11.15 
±0.72 
18.68 
±0.33 
25.73 
±0.54 
35.04 
±0.97 
4 11.73 
±0.45 
18.19 
±0.23 
22.78 
±0.53 
23.77 
±0.98 
16.61 
±0.29 
19.32 
±0.15 
28.73 
±0.04 
30.52 
±0.53 
16.02 
±0.04 
24.04 
±0.52 
34.96 
±0.05 
43.31 
±0.69 
5 14.76 
±0.58 
21.90 
±0.55 
27.36 
±0.89 
27.69 
±0.43 
18.88 
±0.33 
25.07 
±0.22 
33.81 
±0.04 
39.60 
±0.59 
19.67 
±0.33 
29.15 
±0.43 
44.17 
±0.54 
48.90 
±0.17 
6 18.33 
±0.55 
26.82 
±0.50 
33.08 
±0.21 
32.82 
±0.55 
24.76 
±0.24 
31.29 
±0.02 
37.82 
±0.08 
43.82 
±0.81 
27.53 
±0.21 
35.13 
±0.07 
51.30 
±0.05 
55.37 
±1.62 
7 22.26 
±0.49 
28.76 
±0.47 
37.48 
±0.56 
37.60 
±0.59 
29.54 
±1.46 
37.46 
±3.42 
41.97 
±0.03 
47.76 
±0.89 
35.13 
±0.10 
41.24 
±0.47 
58.04 
±0.20 
62.59 
±1.30 
8 26.42 
±0.87 
33.28 
±0.45 
41.35 
±0.53 
41.29 
±0.59 
32.29 
±0.71 
41.95 
±0.20 
47.30 
±0.30 
57.43 
±0.59 
39.91 
±0.01 
48.71 
±0.40 
62.45 
±0.89 
68.06 
±0.15 
9 29.13 
±0.64 
36.86 
±0.98 
45.55 
±0.58 
46.02 
±0.95 
39.82 
±1.09 
47.90 
±0.20 
49.74 
±0.04 
61.49± 
0.41 
44.05 
±0.77 
56.70 
±0.40 
65.64 
±0.51 
74.72 
±0.51 
10 35.21 
±0.89 
39.65 
±0.44 
48.83 
±0.44 
52.41 
±0.69 
44.88 
±0.89 
52.40 
±0.40 
57.53 
±0.50 
68.45 
±0.23 
50.78 
±0.10 
62.31 
±0.17 
73.32 
±0.94 
79.08 
±0.93 
24 45.81 
±0.66 
49.38 
±0.85 
55.98 
±0.48 
59.94 
±0.65 
52.89 
±0.16 
63.59 
±0.30 
86.18 
±0.02 
99.14 
±0.63 
58.04 
±0.20 
76.39 
±0.45 
97.43 
±0.11 
99.01 
±1.00 
*Mean ± SD (n=3) 
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Fig. 7.10: In vitro release study of the tablets 
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In vitro Release Study of Optimized Formulation (F04C2) 
 The in vitro release study of optimized formulation was shown in table 7.24 and            
figure 7.11. 
 
Table 7.24: In vitro Release of Optimized Formulation (F04C2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Mean ± SD (n=3) 
 
 
 
S. No Time in hours Cumulative percentage Drug Release* 
1 0 0 
2 1 9.22±0.026 
3 2 15.89±0.067 
4 3 21.11±0.078 
5 4 27.21±0.038 
6 5 33.90±0.067 
7 6 38.75±0.087 
8 7 45.21±0.028 
9 8 52.03±0.078 
10 9 55.90±0.065 
11 10 62.01±0.042 
12 12 68.89±0.067 
13 14 74.23±0.029 
14 16 83.89±0.098 
15 24 99.13±0.023 
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Fig. 7.11: Release study of optimized formulation (F04C2) 
 The formulatin F04C2 produced the drug release for 24 hours. 
Effect of amount of osmogen on drug release: 
The effect of amount of osmogen on drug release is shown in the figure 7.12 
 
Fig. 7.12: Effect of osmogen concentration on drug release 
 Increase in concentration of mannitol increases the drug release. Higher the amount of 
osmogen, greater is the driving force to release the drug. This is because increase in osmogen 
concentration increases the osmotic pressure inside the tablet and thus the rate of drug release is 
increased.29 
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Effect of concentration of pore forming agents on drug release 
 To study the effect of concentration of pore forming agent(sorbitol), core tablet F04 with 
three different coatings C1, C2, C3 (Formulation F04C1, F04C2, F04C3) containing various 
concentration of sorbitol were selected.  
   
Fig. 7.13: Effect of concentration of pore forming agents on drug release 
  The formulation F04 with C1 coating showed only 52.41% of drug release at the end of 
10 hours due to lack of pore forming agent (0% sorbitol). The formulation F04 with C2 
coating(10% sorbitol) showed drug release of 68.45% at the end of 10 hours. The formulation 
F04 with C3 coating (20% sorbitol) showed faster drug release of 79.08% at the end of 10 hours. 
This shows that the level of pore former increases the membrane porosity resulting in faster drug 
release.29(Figure 7.13) 
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EVALUATION OF OPTIMIZED FORMULATION 
Effect of Agitation Speed on the drug release 
 Drug release under different agitation rates was conducted in order to investigate the 
influence of agitation rate on drug release and the results are shown in table 7.25 and figure 7.14. 
Table 7.25: Effect of Agitation Speed on drug release 
 
Dissolution Medium 
 
Time in hours 
Cumulative % drug release* 
Speed of rotation of the paddle 
50 rpm 100 rpm 150 rpm 
 
Acid buffer pH 1.2 
0 0 0 0 
1 9.29±0.56 8.45±0.55 10.45±0.78 
2 13.06±0.83 14.10±1.11 13.77±0.44 
Phosphate buffer pH 6.8 
3 21.33±0.88 21.05±1.63 21.48±1.41 
4 26.30±1.6 26.15±0.85 26.58±0.62 
5 31.54±0.50 31.33±1.11 31.86±0.14 
6 38.14±0.86 38.11±0.89 38.74±1.26 
7 45.35±0.64 43.73±0.87 48.50±0.40 
8 50.12±0.45 50.98±1.02 51.61±0.84 
9 57.91±1.09 57.40±0.60 57.44±0.90 
10 67.69±0.52 66.72±2.18 68.40±1.04 
24 99.10±0.13 99.32±0.49 99.50±0.28 
*Mean ± SD (n=3) 
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Fig. 7.14   : Effect of Agitation Speed on Drug release 
             The speed of rotation doesn’t have much effect on drug release. Therefore the mobility 
of gastrointestinal tract might scarcely affect the drug release.29 
Effect of Osmotic Pressure on drug release 
 Drug release under different osmotic pressure was conducted in order to investigate the 
influence of osmotic pressure of release medium on drug release and the results are shown in 
table 7.26 and figure 7.15. 
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Table 7.26: Effect of Osmotic Pressure on drug release 
 
Dissolution 
Medium 
 
Time in hours 
Cumulative % drug release* 
Osmotic Pressure of the medium 
1.5 atm. 3 atm. 4.5 atm. 
 
Acid buffer pH 1.2 
0 0 0 0 
1 5.70±0.58 3.76±0.80 3.12±1.12 
2 7.87±0.36 8.72±0.51 6.93±0.41 
 
Phosphate buffer 
pH 6.8 
3 20.38±0.73 19.96±1.27 18.29±1.61 
4 24.11±0.89 22.11±1.10 23.20±1.01 
5 30.09±2.01 28.03±1.18 26.01±1.00 
6 38.02±1.07 35.98±0.25 33.81±0.19 
7 43.22±1.67 43.44±0.79 37.40±0.81 
8 53.45±0.77 48.08±0.95 42.66±0.55 
9 58.98±00.23 56.01±1.20 47.66±1.01 
10 67.94±0.27 61.44±1.46 49.81±2.18 
24 86.85±1.15 72.22±2.78 57.53±1.47 
*Mean ± SD (n=3) 
 
Fig. 7.15: Effect of Osmotic Pressure on drug release 
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 The drug release from the formulation decreased with increase in osmotic pressure of the 
dissolution medium. This confirms that the mechanism of drug release is by osmotic pressure.29 
Effect of pH on drug release 
 In order to study the effect of pH on drug release the optimized formulation (F04C2) was 
subjected to drug release study in different dissolution medium like acid buffer pH 1.2, acetate 
buffer pH 4.5 and phosphate buffer pH 6.8. The results are depicted in table 7.27 and figure 7.16. 
Table 7.27  : Effect of pH on drug release 
 
Time in 
hours 
Cumulative % drug release* 
Acid Buffer pH 
1.2 
Acetate Buffer 
pH 4.5 
Phosphate 
Buffer pH 6.8 
0 0 0 0 
1 9.93±1.07 9.46±1.53 10.16±2.82 
2 14.80±1.40 14.86±0.35 14.92±0.42 
3 21.29±0.61 21.10±1.90 23.73±2.26 
4 28.47±0.83 29.06±1.17 29.01±1.11 
5 33.09±1.41 35.01±1.37 36.21±1.78 
6 38.2±4.20 38.69±0.54 42.35±0.86 
7 44.84±0.00 44.42±1.47 47.73±1.05 
8 52.63±0.63 51.34±0.78 54.47±0.86 
9 58.73±0.07 58.40±0.83 59.06±2.17 
10 67.61±0.20 65.33±1.79 65.55±1.45 
24 99.45±0.45 99.13±0.63 99.21±0.36 
    *Mean ± SD (n=3) 
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    Fig 7.16 : Effect of pH on drug release 
  The pH of  release medium does not have significant effect on drug release. Therefore 
the pH of gastrointestinal tract might scarcely affect the drug releaase.22 
Membrane Morphology of porous Osmotic Tablets 
 Membranes obtained before and after dissolution was studied using scanning electron 
microscope. Membranes obtained before dissolution showed non porous region                        
(Fig 7.17a, 7.18a). After 24 hours of dissolution the membrane showed pore formation owing to 
the dissoution of sorbitol from the membrane (Fig 7.17b, 7.18b) and thus the release of drug 
takes place. Coating solution C2 containing 10% sorbitol was coated on the formulation F04 
produced less pores compared to formulation F04 coated with the coating solution C3 containing 
20% sorbitol (Figure 7.17 a,b & 7.18 a,b). 
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                  a) Before Dissolution                                                         b) After Dissolution 
                                   
Fig. 7.17 : Membrane Morphology of Formultion F04C2 by Scanning 
Electron Microscope 
     a) Before Dissolution                                                             b) After Dissolution 
                                           
Fig. 7.18 : Membrane Morphology of Formultion F04C3 by Scanning 
Electron Microscope 
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Release Kinetics of the Optimized Formulation 
 The dissolution data of the optimized formulation was fitted to various kinetic models 
and the reults are tabulated in table 7.28  and figures 7.19 to 7.23. 
Table 7.28 : Release Kinetics of the Optimized Formulation 
Time  
(hours) 
Log 
time 
(Hours) 
Sq. root 
of time 
(hours) 
Cum % 
drug 
release 
Cum % 
Drug 
remaining 
Log 
Cum % 
drug 
release 
Log cum 
% drug 
remaining 
Cube root 
of cum % 
drug 
remaining 
0 - 0 0 100 - 2.00 4.64 
1 0 1 9.22 90.78 0.96 1.96 4.49 
2 0.30 1.14 15.89 84.11 1.20 1.92 4.38 
3 0.48 1.73 21.11 78.89 1.32 1.89 4.29 
4 0.60 2.00 27.21 72.79 1.43 1.86 4.18 
5 0.70 2.24 33.90 66.10 1.53 1.82 4.04 
6 0.77 2.44 38.75 61.25 1.59 1.79 3.94 
7 0.85 2.65 45.21 54.79 1.66 1.74 3.80 
8 0.90 2.83 52.03 47.97 1.72 1.68 3.63 
9 0.95 3.00 55.90 44.10 1.75 1.64 3.53 
10 1.00 3.16 62.01 37.99 1.79 1.60 3.36 
12 1.07 3.46 68.89 31.11 1.84 1.49 3.15 
14 1.15 3.74 74.23 25.77 1.87 1.41 2.95 
16 1.20 4.00 83.89 16.11 1.92 1.20 2.53 
24 1.38 4.90 99.13 0.87 1.99 -0.06 0.95 
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Fig. 7.19 :  Plot of zero order kinetics 
 
Fig. 7.20 : Plot of first order kinetics 
 
Fig. 7.21 : A Plot of Higuchi kinetics 
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Fig. 7.22: Plot of Korsmeyer and Peppas Kinetics
Fig. 7.23: Plot of 
 The coefficient of determination (R
appropriate model. The R2 values of various models are in table
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Hixson-Crowell Kinetics 
2) was taken as criteria for choosing the most 
 7.29.  
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The in vitro drug release of the optimized formulation F04C2 was best explained by 
Hixson Crowell as the plots showed the highest linearity (R2=0.9815) followed by zero order 
(R2=0.9443). The Hixson Crowell plot indicated a change in surface area and diameter of the 
tablets with progressive dissolution of the tablet as a function of time.84 
STABILITY STUDY 
After storage, the formulation F04C2 was subjected to evaluation of physical parameters, 
drug content and in vitro drug release. The results are tabulated in table 7.30 & 7.31. 
                                               Table 7.30 : Stability Studies 
Parameter Initial 1st  Month 2nd  Month 3rd  Month 
Description Yellow round 
concave 
coated tablets 
Yellow round 
concave 
coated tablets 
Yellow round 
concave coated 
tablets 
Yellow round 
concave coated 
tablets 
Diameter* (mm) 8.966±0.0151 8.952±0.0311 8.978±0.0356 8.954±0.0309 
Thickness*(mm) 3.570±0.0330 3.542±0.0148 3.574±0.0190 3.570±0.0178 
Hardness* (kg/cm2) 5.8±0.5700 5.7±0.2738 5.7±0.5734 5.8±0.3209 
Drug 
content*(%w/w) 
98.33±1.123 99.08±1.098 98.34±1.134 99.18±1.1290 
*Mean ± SD (n=5) 
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Table 7.31: In vitro release study before and  during stability study 
Dissolution 
Medium 
Time in hours 
Cumulative % drug release* 
Initial 1st Month 2nd Month 3rd Month 
Acid buffer 
pH 1.2 
0 0 0 0 0 
1 09.00±0.05 8.37±0.75 7.75±0.46 7.34±0.50 
2 11.50±0.49 12.05±1.84 12.10±0.21 12.89±0.19 
 
Phosphate 
Buffer pH 
6.8 
3 21.63±0.26 24.34±0.65 22.44±0.51 24.37±0.44 
4 30.52±0.53 30.02±1.10 29.83±0.68 29.71±0.39 
5 39.60±0.59 41.14±0.86 39.11±0.85 39.93±1.03 
6 43.82±0.81 43.75±1.06 44.07±0.12 44.77±0.51 
7 47.76±0.89 47.26±0.95 49.50±1.53 50.56±0.48 
8 57.43±0.59 56.21±1.79 56.40±0.42 57.41±0.42 
9 61.49±0.41 60.19±0.93 63.34±0.67 64.97±0.13 
10 68.45±0.23 69.71±0.31 69.82±0.57 69.79±0.70 
24 99.14±0.63 99.51±0.36 98.44±1.44 98.00±0.69 
       *Mean ± SD (n=3) 
 When the osmotic tablets were stored at 400C±2ºC / 75±5% RH for 3 months there 
appeared no change either in physical appearance or in drug content. When the dissolution study 
was conducted in the simulated physiological environment of stomach (pH 1.2) and intestine (pH 
6.8), not much difference was observed in the cumulative percentage release of Lornoxicam 
from F04C2. 
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 The aim of the present study was to develop a controlled porosity osmotic tablet of LOX 
and to evaluate the in vitro release of the drug from the system. The osmotic tablet is developed 
such that it delivers 8 mg of LOX over a period of 24 hours. 
 Drug – Excipient compatibility study was carried out using FTIR study. The results 
showed that there was no interaction between them. 
 Calibration curves of LOX were constructed in three different pH; Acid buffer pH 1.2, 
Acetate buffer pH 4.5 and phosphate buffer pH 6.8. 
 Wet granulation produced excellent flow and the granules were compressed on 9/32 
concave punches into tablets. The tablets were then coated with a controlled porosity 
semipermeable membrane of CA with sorbitol as pore former. 
 The post compression parameters namely uniformity of weight, thickness, diameter, 
hardness, drug content and uniformity of content were evaluated for the coated and 
uncoated tablets and were found to be within limits. 
 The in vitro study was carried out for 2 hours in 0.1N HCl buffer pH 1.2 and for 22 hours 
in phosphate buffer pH 6.8. 
 Among the different formulations, F04C2 gave satisfactory results by releasing 99.13% 
of LOX in 24 hours. 
 The drug release was found to increase with increase in the osmogen content. 
 Variation in the speed of rotation of the paddle did not alter the release to a greater extent. 
Increase in osmotic pressure of the medium decreased the drug release. 
 The release study was conducted in different release medium like Acid buffer pH 1.2, 
Acetate buffer pH 4.5, and Phosphate buffer pH 6.8. Variation in pH does not affect the 
release to a greater extent. 
 To describe the mechanism of drug release, the optimized formulation was fitted to 
various models. The drug release was found to follow zero order and Hixson Crowell 
release. 
 The accelerated stability testing was carried out for 3 months and showed no change in 
the appearance, hardness, diameter, thickness, friability, drug content and in vitro release. 
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 Of the several formulations investigated, the formulation (F04C2) containing 60% 
mannitol in the core tablet as osmogen and 10% of sorbitol in the semipermeable 
membrane as pore former has come out successfully to comply with the requirements for 
controlled release formulations. The osmotic pressure exerted by the osmogen in the core 
tablet and the amount of pore former in the semipermeable membrane controlled the drug 
release.    
Future Scope 
 Gamma scintigraphy is required to be done to ensure that the release starts in the upper 
part of GIT. 
 Stability studies – Short term and long term to be carried out. 
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